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CHAPTER I 
 
 
INTRODUCTION 
 
 
 With the recent advances in the human genome project and with the International 
HapMap project adding information on millions of SNPs to the knowledge base, the 
feasibility of applying large-scale and even genome-wide association studies for complex 
disease and quantitative traits is fast approaching.  Recent advances in SNP genotyping 
techniques now support genome-wide profiling of hundreds of thousands, even millions, 
of SNPs in parallel with proven accuracy.  These technologies allow for a hypothesis 
generating approach to identifying disease associated alleles without a priori knowledge 
or candidate genes or regions.  One obstacle in the progression towards whole-genome 
association studies for complex diseases and quantitative traits is the high cost of projects 
that are appropriately statistically powered for association analysis.  For example, if 
disease associated alleles have a minor allele frequency (MAF) of less than 0.1 and an 
effect size less than an odds ratio of 1.3, then the sample size needed for an association 
study with a statistical power of >80% at a significance level of p-value < 1e-6 would be 
more than 10,000 cases and an equal number of controls [1].  While the natures of MAF 
and odds ratios are not comprehensively characterized for complex diseases and 
quantitative traits, the sample size requirements in the above example are not extreme.  In 
a 2007 review by Couzin and Kaiser, the results of several genome-wide association 
(GWA) studies are listed [2].   Table 1 summarizes these results with respect to sample 
size, number of disease associated variants, and the increased disease risk attributed to 
the variants.  
Table 1: Review of Genome
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-Wide Association study results
Couzin and Kaiser [12]
: 
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 In another review of currently known quantitative trait loci (QTL), approximately 
half of the candidate causal variants had MAFs of less than 0.05 [3], and the odds ratios 
and relative risks of known disease associated variants often occur in the range between 
1.1 and 1.5 [4, 5]. Therefore, individually genotyping the thousands of individuals 
necessary to achieve proper statistical results could rapidly become a multi-million dollar 
undertaking, prohibitive for all but the most highly funded labs. 
 A potential solution to the prohibitive cost of individual genotyping is to combine 
genomic DNA from case individuals and an equal number of control individuals and to 
genotype the pooled DNA.  Pooling designs for association studies of complex disease 
such as Alzheimer’s [6], sudden infant death with dysgenesis of the testes [7], and mild 
mental impairment [8] have had promising results.  However, using pooling as a general 
approach to identify complex disease associated genes remains controversial.   
 While pooling has obvious advantages in that fewer genotyping assays result in 
substantial cost and time savings, questions arise as to the ability to detect the causal or 
associated alleles with small effect size and/or low frequencies in the pooled samples 
versus the individually genotyped samples. Further, the characteristics of information 
obtained relative to individual genotyping need to be explored in order to determine the 
overall validity of DNA pooling for genome-wide association analysis.  In this study, we 
propose to examine the feasibility of a pooling approach for whole-genome association 
studies of complex disease.  Using a simulated genome dataset, we will compare and 
evaluate the advantages and disadvantages of DNA pooling versus individual genotyping.  
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 The genetic architectures of common disease are the results of complex 
interactions from multiple alleles, as well as gene-environment and gene-gene 
interactions.  The allelic spectrum of complex disease can be modeled as interplay 
between the number of disease variants, the risks that these variants confer, and the 
frequencies with which they occur in the population.  Taking these factors into account, 
the statistics of association studies and the power which they can bring to that study will 
emerge. 
 Two models of the characteristic patterns of common or complex diseases have 
been proposed.  First, the common disease/common variant hypothesis suggests that a 
disease results from the multiplicative action of several common variants.  Unrelated 
affected individuals have a significant proportion of disease alleles in common, hence the 
term “common variant” [3, 9].  In the case of this multiplicative model, the combined 
effect of multiple disease associated alleles contributes exponentially as opposed to 
linearly.  In contrast, the classical disease heterogeneity hypothesis (or multiple rare-
variant hypothesis) suggests that disease susceptibility is due to rare and distinct variants 
in different individuals which contribute additively [10].  The additive model of complex 
disease states that each disease associated allele contributes equally to the overall disease 
risk.  Studies have shown evidence for an additive characteristic spectrum in some 
cancers [11] and type 2 diabetes [12-14] and a multiplicative effect in type 1 diabetes 
[15].   
 There are two main methodologies for identifying complex disease genes.  The 
first are candidate gene studies using either association or resequencing protocols.  
Association candidate gene studies have the advantage of being relatively inexpensive 
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and are able to detect alleles with modest effect size, given that these alleles are common 
in the population (MAF>0.05).  However, both association and resequencing candidate 
gene studies require prior information about gene function.  The second approach for 
identifying common disease variants is to use genome-wide studies: either linkage 
mapping or genome-wide association.  Although genome-wide linkage analysis has been  
successful, its greatest power lies in identifying Mendelian diseases which are 
characteristically monegenic and highly penetrant [16].  In contrast, complex diseases are 
typically the result of multiple causal loci each with low penetrance.  Thus, linkage 
studies for complex disease have had only limited success and limited reproducibility. 
For example, disease variants have been found in inflammatory bowel disease, which 
account for a two-fold increase in risk in siblings [17-20]. Yet it has been shown that a 
greater than a thirty-fold risk increase exists overall for this disease, pointing to the 
existence of other genes not resolved by the linkage study design [21].   The power of 
linkage analysis decreases sharply as effect of complex disease genes becomes less 
penetrant [22-25].  Linkage analysis is more powerful than association analysis for 
identifying rare, highly penetrant alleles, but association analysis is expected to be more 
powerful for identifying complex disease alleles with modest disease risks [22].  Because 
linkage analysis is done in families, the resulting regions of linkage correlating with 
disease are relatively large, often on the order of 10cM or more (~10 million base pairs).  
Therefore, extensive candidate gene analysis (either by resequencing or association 
studies) must follow in order to find the causal genes within the linked region [16].   
 Genome-wide association studies offer the advantage of not needing prior 
information about linkage or of candidate genes in order to attain associated alleles in 
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complex diseases.  In contrast to candidate gene based studies, genome-wide association 
will be unbiased and, if designed properly, also fairly comprehensive in terms of 
extracting a significant portion of the genomic variation.  A crucial advance made 
possible through the HapMap project is the characterization of linkage disequilibrium 
(LD) patterns on a genome-wide scale [26, 27].  This is important for indirect association 
methods that use markers selected on the basis of LD.  To be useful, markers tested for 
association must either be the causal allele (direct association) or in LD with the causal 
allele (indirect association) [28, 29].  Roughly 70-80% of the genome falls into segments 
of strong LD and variants with high LD are strongly correlated with each other [30].  
Most of the ~11 million common SNPs (MAF>0.01) in the genome have groups of 
neighbors that are all nearly perfectly correlated with each other [28].  One SNP can 
thereby serve as a proxy for many others in an association screen. Overall, this suggests 
that if patterns of LD are known for a given region, a few tagSNPs can be chosen which, 
either individually or in multimarker combinations (haplotypes), capture most of the 
common variation within the region [31, 32].  Thus, it has been proposed that much of 
the common variation in the genome can be found by genotyping a few hundred thousand 
“well-chosen” SNPs [33, 34].  For the remaining fraction of the genome that is not in LD 
(20-30%), higher densities of variants must be typed.  Such a scan is estimated to require 
two hundred thousand to one million markers to achieve a reasonable likelihood that any 
common SNP in the genome is usefully associated with at least one tagSNP [35]. Current 
genotyping technologies make use of a “tagSNP” centered approach such as Illumina’s 
“HumanHap” series of whole-genome beadchips.    
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Advantages and disadvantages of pooled genotyping for genome-wide association 
analysis:  
 
 “In their simplest form, association studies compare the frequency of alleles or 
genotypes of a particular variant between disease cases and controls.” (Wang 2005 [1])  
 
 The pooling approach lends itself well to association studies as the allele 
frequencies themselves are the results and outputs of pooled genotyping.  The major 
benefit of DNA pooling is that it reduces the amount of genotyping that is required to 
estimate allele frequencies, as fewer SNP chips are utilized.  Additionally, as a direct 
result of less genotyping, the time of analysis is also reduced.  Thus, the efficiency of 
pooling is directly correlated with the number of samples pooled.  These pools could be 
constituted from cases and controls for a disease trait, or from individuals with values at 
the two extremes of a quantitative trait.  Studies have been done where the optimal tails 
of quantitative trait distributions have been derived [36].  In a symmetrical design, taking 
the top and bottom 27% of trait distributions and pooling them extracts 80% of the total 
information compared to individual genotyping for common alleles with an additive 
effect [36].  These results do not generalize to recessive or rare alleles however, in this 
case an asymmetrical design is needed [37].  
 The degree of power conferred by pooling is highly influenced by the effect size 
of the causal variants.  Alleles which have large relative risks will directly lead to large 
differences in allele frequency estimates between cases and controls.  However, there will 
likely be small differences between case and control allele frequencies in complex 
disease because of the small increase in relative risks resulting from modest risk alleles.  
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The ability to detect the real allele frequency difference is dependent on the differences in 
allele frequencies between cases and controls, and the errors and variances in estimating 
them.  This error in allele frequency estimates for pooling comes from two main sources: 
sampling error and measurement error [38].  Measurement error results from “poor 
quality DNA” which has degraded, or from platform genotyping error.  Measurement 
error is present in both individual and pooled genotyping.  Sampling error results from 
uneven DNA contributions to the pool from individuals and platform errors in allele 
frequency estimation.  Proper DNA mixing can be controlled by careful measurement 
and mixing of equal amounts of DNA into the pool with the use of robotics and highly 
sensitive DNA quantitation protocols such as Picogreen.  Increasing sample size reduces 
sampling error, but not measurement error.  Estimated allele frequencies from pools have 
consistently been found to have standard deviations between 2-4% due to errors resulting 
from the genotyping platforms [38].  In the case of complex disease where modest-risk 
alleles with small effect size are likely, even small allele frequency estimate errors can 
dramatically reduce the power of a pooled methodology.  In a simulation study, it was 
shown that the variance resulting from sampling error was potentially more significant 
than the variance resulting from measurement error [39].  Thus, pooling designs have the 
disadvantage of having an additional source of error, namely sampling error, which is not 
present in individual genotyping.   
One major disadvantage of pooling is that the haplotype information is not 
resolvable as only allele frequencies are determined by pooled genotyping.  This actually 
makes the term “pooled genotyping” a bit misleading.  Pooled “allelotyping” has been 
suggested as the allele frequencies are the results from a pooled experiment.  There are 
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special circumstances where haplotype information can be obtained from a pooled 
sample.  For pool sizes of less than 10 individuals per pool, it is possible to determine 
haplotype frequency estimates using the expectation-maximization (EM) algorithm [40].  
However, these are not true haplotypes in terms of the genotype information and their 
chromosomal location.  Rather, the frequency estimates of the haplotypes in the sense of 
the population.   
A potentially useful outcome of the loss of haplotype information by pooling may 
be realized.  This inability to identify individual haplotypes from a pooled DNA sample 
effectively de-indentifies the individuals in the pooled groups. 
 The high number of genotype tests involved in a whole-genome association study 
will certainly lead to many false positives.  If a liberal significance threshold of (p-value 
<0.05) is used, approximately 5,000 false positives will result from a 100,000 SNP gene 
chip.  Applying a more stringent p-value cutoff such as 5x10-7, (P-value = 0.05) which 
has been Bonferroni corrected for 100,000 independent tests, will lower the number of 
false positives but also risks making the testing too stringent and may lead to missed 
associations.  The ultimate choice of stringency cutoff is best left to the circumstances of 
the experiment.  This is an area of active research.  Three likely sources of false positives 
are statistical fluctuations from random noise, underlying systematic biases due to study 
design, and technical artifacts.   
 
Conclusions of introduction: 
 This study is firstly an exploration to address the feasibility of DNA pooling for 
whole-genome association analysis of complex disease.  While previous research has 
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shown encouraging gains in efficiency by pooling for several diseases (including 
Alzheimers’) [5,6], this may be specific to the nature of disease in question and not 
generalizable.  There have also been well structured designs to explore the impact of 
genotyping and experimental errors in pooling designs in terms of the change in sample 
size needed to achieve valid statistical results [39].  The effect of genotyping error on the 
haplotype frequency estimates has also been explored [40].  To our knowledge, a 
comprehensive analysis of the tradeoffs involved in a pooling design versus individual 
genotyping has not been systematically addressed.  Additionally, there have been 
limitations at generating complex disease models which are good approximates of the 
diseases.  Put simply, the previous generations of genotype simulation software does not 
allow for models with enough complexity to sufficiently represent a complex disease.  
This study aims to create and evaluate a more complex model of common disease.  The 
International Haplotype Mapping project (HAPMAP) has defined the genome with a 
much high degree of resolution than ever before [26, 27, 35, 41].  Commercially available 
genotyping platform technologies allow genotype scanning at progressively higher 
densities.  The convergence of technology and knowledge presents an opportunity to 
begin true genome-wide association analysis.  
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CHAPTER II 
 
 
COMPLEX DISEASE MODEL MATHEMATICS 
 
 
Pooled genotyping association testing statistic: 
 The appropriate test for this two-pool design would be to consider the magnitude 
of the difference between the allele frequency estimates of the two pools in relation to its 
variance. The standard Pearson’s chi-squared test assumes that the variance of the 
difference in allele frequency estimates is determined entirely by sampling variation 
alone. This does not apply to pooling because the variance will be inflated by sampling 
and allele frequency measurement errors that are specific to DNA-pooling studies [36, 
37, 42-44]. These additional errors can potentially increase the number of false-positive 
association findings. 
 Equation 1 shows the appropriate test statistic for allelic association for two 
independent pools. 
 
Equation 1: Pooled genotyping association testing statistic 
     

 

 
 
 Equation 1 states that pooled association statistic testing is calculated by taking 
the difference in allele frequency measurements on the two pools (p1 and p2), squaring 
that difference, and dividing by the sum of two variances (V1 + V2).  V1 is the variance in 
allele frequency estimates due to platform measurement error. V2 is variance in allele 
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frequency estimates due to sampling error.  Measurement error variance (V1) of the allele 
frequencies results mainly from the genotyping platform itself [38] or by degraded “bad 
quality” DNA resulting in genotyping errors.  Sampling error variation (V2) is attributed 
mainly to unequal amounts of DNA used to construct the pools by imprecise 
quantification and inaccurate mixing, and by signal measurement error by the genotyping 
platform.  Both of these sources of sampling error skew the allele frequency estimates.  
Under the null hypothesis and with a two pooled design, Z2 is approximately distributed 
as a  chi square distribution with one degree of freedom [37], given a sample size of 100 
or more [45]. 
 Due to the nature of complex disease alleles having a modest effect size, it has 
been shown that taking the mean association test statistic for consecutive markers can be 
more informative than single point association.  Using a moving windows approach 
where consecutive marker groups of varying window size are tested takes advantage of 
the fact that markers in LD will be reciprocally predictive of each other.  If markers are 
not in LD, permutation testing can be used in order to ascertain the significance of a 
window group [7]. 
 
Complex disease model characteristics: 
 There are two thoughts as to how the allelic profile of complex disease can be 
modeled.  These two models are not so much competing views as they are 
complementary possibilities of how complex disease might look at the genetic level.  
Firstly, the additive model hypothesizes that each disease associated allele contributes 
roughly equally in terms of increased disease risk, and that numerous instances of these 
13   
disease associated alleles have an additive effect [1].  This additive model is also termed 
the disease heterogeneity model as the disease risk increases linearly with the number of 
risk alleles present.   
 The contrasting model proposed for complex disease is the multiplicative model.  
It states that disease risk increases exponentially with increasing numbers of disease 
associated variants present.  Evidence for both additive and multiplicative types of 
complex disease allelic spectra exists in the field.  For example, type 2 diabetes has been 
shown to display an additive characteristic of disease contribution by several alleles of 
modest effect [14, 46, 47] while type 1 diabetes may be multiplicative[12].  In order to 
build these two models into our genotype simulation package (genomeSIM), penetrance 
tables were constructed in order to represent the additive and multiplicative models.  The 
disease risk calculations for both the additive and multiplicative models have been set to 
include a phenocopy rate of 10%.  This is the disease risk due to environmental factors, 
as well as other non-genetic factors.  A graph of the two types of complex disease models 
taken from a review by Wang et. al. is shown in Figure 1.  It relates the probability of 
disease between the two model types versus genetic relatedness.  
  
 Figure 1: Schematic representation of allelic spectrum of 
Heterogeneity (Additive)
(Multiplicative) complex disease models
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 and Common Disease Common Variant 
 
Wang et. al. 
 
[1] 
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Complex disease models for construction of simulated genotypes:  
 The method of calculating the disease probability values in the penetrance tables 
was derived using a generalized relative risk model for complex disease proposed by 
Risch and Teng [48].  This genetic model serves as a general framework for assigning a 
disease penetrance to a corresponding genotype.  If a disease locus contains alleles “D” 
for wild-type and “d” for a disease associated variant, then the penetrance associated with 
the disease genotypes can be represented as DD = f0, Dd = f1, and dd = f2.  Given this 
representation, disease models can then be expressed in terms of relative penetrance or 
genotypic risk ratios [22].  It follows that if the risk associated with the wild-type 
genotype “DD” is fixed at f0=1, then the risk associated with a single diseased allele 
heterozygote, (“Dd” = f1), can be expressed relative to the f0.  Further, the risk associated 
with two disease alleles, (“dd” = f2), can also be expressed relative to the f1 and the f0.  
The additive and multiplicative complex disease models can then be defined in terms of 
the f0, f1, and f2 penetrance values.  For the additive model the formula [f2 = 2(f1) – f0] 
describes the relationship.  A multiplicative model can be represented by [f2 = f12][48].  
These models are for a single locus and allow for representation of a three state model, 
namely [DD = f0; Dd = f1; and dd = f2]. So an additive model with a relative risk of 5 
might be defined by the following parameters: DD (f0 = 0.1) corresponding to wild type 
genotype with a 10% probability of having the disease, Dd (f1 = 0.5) corresponding to a 5 
fold increase in disease probability given the presence of one disease associated allele, 
and if both alleles are disease variants, dd (f2 = 0.9) calculated by application of the 
additive complex disease model formula [f2 = 2(f1)-f0] -> [f2 = 2(0.5)-0.1] -> f2 = 0.9.   
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 Our evaluation applied the Risch and Teng complex disease formulas to a three 
locus model involved a stepwise expansion of the penetrance function relationships to the 
genotypes and consequent expansion of the model formulas themselves.  A one locus 
model will have 3 possible states corresponding to [DD = f0, Dd = f1, dd=f2].  Expanding 
this to a two locus biallelic model (genes “A” and “B”) will give 9 possible genotypic 
states [AABB, AABb, AAbb, AaBB, AaBb, Aabb, aaBB, aaBb, aabb].  These 9 states are 
the result of the 3 possible genotype states for each of the 2 loci.  The combinatorics 
result from the number of possible states for each bi-allelic locus (3) raised to the number 
of loci (2), [32 = 9].  Accordingly, a 3 locus model will have 33 = 27 possible genotype 
states.  For this study, each of the model states is represented analogous to the Risch and 
Teng model as a genotype and corresponding penetrance probability. Penetrance Table 1 
shows a penetrance function in which the additive and multiplicative disease probabilities 
were calculated for the 27 genotypes of each model. 
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Table 2: Penetrance Table 1 for Relative Risk Range 1.08 to 1.50 
 
Uppercase [A, B, or C] denotes non-disease associated allele 
Lowercase [a, b, or c] denotes disease associated variant allele 
 
Heterozygotes for single disease variant locus highlighted in yellow 
Homozygotes for 2 disease variant allele locus highlighted in blue 
 
Disease Associated 
Locus   Disease Risk (Probability) 
A B C Genotype Additive Multiplicative 
AA BB CC AABBCC 0.1000 0.1000 
Aa BB CC AaBBCC 0.1083 0.1070 
AA Bb CC AABbCC 0.1083 0.1070 
AA BB Cc AABBCc 0.1083 0.1070 
aa BB CC aaBBCC 0.1167 0.1145 
Aa Bb CC AaBbCC 0.1167 0.1145 
AA bb CC AAbbCC 0.1167 0.1145 
Aa BB Cc AaBBCc 0.1167 0.1145 
AA Bb Cc AABbCc 0.1167 0.1145 
AA BB cc AABBcc 0.1167 0.1145 
aa Bb CC aaBbCC 0.1250 0.1225 
Aa bb CC AabbCC 0.1250 0.1225 
aa BB Cc aaBBCc 0.1250 0.1225 
Aa Bb Cc AaBbCc 0.1250 0.1225 
AA bb Cc AAbbCc 0.1250 0.1225 
Aa BB cc AaBBcc 0.1250 0.1225 
AA Bb cc AABbcc 0.1250 0.1225 
aa bb CC aabbCC 0.1333 0.1310 
aa Bb Cc aaBbCc 0.1333 0.1310 
Aa bb Cc AabbCc 0.1333 0.1310 
aa BB cc aaBBcc 0.1333 0.1310 
Aa Bb cc AaBbcc 0.1333 0.1310 
AA bb cc AAbbcc 0.1333 0.1310 
aa bb Cc aabbCc 0.1417 0.1402 
aa Bb cc aaBbcc 0.1417 0.1402 
Aa bb cc Aabbcc 0.1417 0.1402 
aa bb cc aabbcc 0.1500 0.1500 
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 The penetrance values are calculated using an expansion of the additive and 
multiplicative model formulas.  The f0 corresponds to the wild-type genotype of 
“AABBCC” in which there are no disease associated SNPs present.  The penetrance 
probability for the f0 is set in this baseline state as 10% to account for phenocopy and 
other non-genetic factors.  The f1 for the 3 gene model concatenates three analogous f1 
heterozygotes for each SNP, thus the genotype “AaBbCc” represents the f1 for the 3 
locus model and has 3 disease associate alleles present.  It follows that the f2 is 
represented by the “aabbcc” genotype, having the maximum possible 6 disease associated 
variants.  The formula proposed by Risch and Teng for an additive common disease 
model is shown in Equation 2.  
 
Equation 2: Additive complex disease model developed by Risch and 
Teng [22] 
 
2   2
1  
0 
 
 The penetrance values corresponding to the genotypes were calculated for the 
expanded additive model.  The set of penetrance probability endpoints were chosen to the 
f2 genotype of “aabbcc” corresponding to all 6 alleles being of the disease associated 
form in all 3 genes.  The range of the penetrance endpoints resulted in ten penetrance 
functions being created.  The endpoint penetrance values used the following probabilities 
for the f2: [0.15, 0.20, 0.30, 0.40, 0.50, 0.60, 0.70, 0.80, 0.90, and 1.0].  These f2 
endpoints were chosen to cover a range of relative risks between the f0 and f2 from 
relative risk 1.5 to relative risk 10 if all 6 alleles are of the disease associated form.  
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Knowing the probability values f0 and f2 allows for deriving the f1 for the “AaBbCc” 
heterozygote genotype for each of the ten penetrance function calculations.  This is 
shown in Derivation of Equation 3, and results in Equation 3.  
 
Derivation of Equation 3: solving f1 of additive complex disease model 
using equation 2 
 
2   2
1   
0  (Equation 2) 
  
1    

  (Equation 2 solved for f1) 
 
Equation 3:  Calculation of f1 penetrance probability for additive 
complex disease model  
 
1   
2   
02  
 
For example, using the baseline f0 = “AABBCC” (with its penetrance probability of 0.10) 
and f1 = “aabbcc” with probability of 0.15, the f1 can be calculated and is shown in 
Sample Calculation for Equation 3. 
 
Sample calculation for Equation3: calculation of f1 in additive model given 
penetrance probabilities (f0 = 0.1) and (f2 = 0.15) 
 
1  0.15  0.12  
  
1   0.252  
  
1   0.125 
 
 The penetrance probability values for the remaining genotypes were calculated by 
stepwise filling in of the intermediate probabilities based of number of disease associated 
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alleles present in the genotype.  For each model genotype, the penetrance value was 
calculated by taking the difference in the probabilities from the f0 and f1, subsequently 
dividing by 6 (the total number of alleles) and multiplying by the number of disease 
associated alleles present in the genotype as shown in equation 4.  The result is an 
additively linear model of disease penetrance probability with respect to the number of 
disease associated alleles present in the genotype.   
 
Equation 4: General penetrance probability calculation for additive 
complex disease model  
 
f = [ f0 + 
2   
0/6 ] * (number of disease associated alleles) 
 
 The multiplicative model calculations were based on an expansion of the Risch 
and Teng complex disease model.  Their formula for a multiplicative effect model in a 
single locus of bi-allelic gene”A” yields three possible states, “AA”, “Aa”, and “aa”. 
These genotype states and their corresponding associated penetrace probabilities are 
represented by [f0, f1, and f2].  Therefore, f0 = “AA” wild-type (and its corresponding 
penetrace probability), f1 = “Aa” heterozygote with 1 disease associated allele, and f2 = 
“aa” homozygote with two disease associated alleles all genotypes having a 
corresponding penetrance probability.  The associated penetrance probabilities of the 
multiplicative model for a single locus model follow the formula in Equation 5.  
 
Equation 5: Multiplicative complex disease model proposed by Risch and 
Teng [22] 
 
2   
1 
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 This formula was the basis for calculating the penetrance functions for a three 
locus multiplicative model.  As with the additive model, the f0 representing the wild-type 
genotype “AABBCC” having no disease associated alleles.  This f0 was set to a 0.10 
penetrance probability, meaning a 10% disease risk given no disease associated SNPs are 
present. This is meant to account for environmental and other non-genetic mechanisms of 
disease contribution.  The same f2 probability endpoints were taken as the additive model 
[0.15, 0.20, 0.30, 0.40, 0.50, 0.60, 0.70, 0.80, 0.90, and 1.0].  The penetrance values for 
the f1 were calculated by taking the square root of the relative risk of the f2 with respect 
to the f0, and then multiplying by the penetrance probability of the f0.  For example, in 
the f0 = [“AABBCC” with a penetrance probability of 0.1] and the f2 = [“aabbcc” with a 
probability of 1.0], then the relative risk (f2/f0) = 10.  The f1 is calculated by taking the 
square root of the relative risk and multiplying by the f0.  This calculation form is shown 
in the sample calculation for Equation 6.  
 
Equation 6: f1 penetrance probability for multiplicative complex disease 
model  
 
1   
0     
2
0  
 
Sample calculation for Equation 6: f1 in multiplicative complex disease 
model given [f0 = 0.1] and [f2 = 1.0] 
 
1   
0     
2
0  
  
1   0.1   1.00.1    
1   0.1  √10  
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  
1   0.1   3.162   
1   0.3162 
  
 The penetrance values for the remaining genotypes having 1, 2, 4 or 5 disease 
associated alleles were calculated by taking the sixth root of the f2 relative risk and 
multiplying by the number of disease associated alleles present in the genotype as shown 
in Equation 7 and Sample Calculation for Equation 7.  
 
Equation 7: General penetrance probability calculation for 
multiplicative complex disease model  
 
Penetrance probability for multiplicative complex disease model = ## $%#   
0   &  '

(  
 
Sample calculation for Equation 7: multiplicative complex disease model for 
genotype with 2 disease associated alleles given f0 = 0.1 and f2 = 1.0 
 
Penetrance probability = ## $%#   
0   &  '

(  
 Penetrance probability = 2 * 0.1 * &  '.
.
(   Penetrance probability = 2 * 0.1 * √10   Penetrance probability = 0.2 * 1.468  Penetrance probability = 0.2154 
 
 Figure 2 shows a graph of the penetrance function for additive and multiplicative 
disease models with an f0 = 0.10, and f2 = 1.0.  The penetrance function for the graph is 
shown in Penetrance Table 10.  
  
 Figure 2: Graph of penetrance functions for 
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Table 3: Penetrance Table 10 for Relative Risk Range 2.5 – 10.0 
 
Uppercase [A, B, or C] denotes non-disease associated allele 
Lowercase [a, b, or c] denotes disease associated variant allele 
 
Heterozygotes with 1 disease allele variant highlighted in yellow 
Homozygotes with 2 disease associated variant alleles highlighted in blue 
 
Disease Associated 
Marker   Disease Risk (Probability) 
A B C Genotype Additive Multiplicative 
AA BB CC AABBCC 0.1000 0.1000 
Aa BB CC AaBBCC 0.2500 0.1468 
AA Bb CC AABbCC 0.2500 0.1468 
AA BB Cc AABBCc 0.2500 0.1468 
aa BB CC aaBBCC 0.4000 0.2154 
Aa Bb CC AaBbCC 0.4000 0.2154 
AA bb CC AAbbCC 0.4000 0.2154 
Aa BB Cc AaBBCc 0.4000 0.2154 
AA Bb Cc AABbCc 0.4000 0.2154 
AA BB cc AABBcc 0.4000 0.2154 
aa Bb CC aaBbCC 0.5500 0.3162 
Aa bb CC AabbCC 0.5500 0.3162 
aa BB Cc aaBBCc 0.5500 0.3162 
Aa Bb Cc AaBbCc 0.5500 0.3162 
AA bb Cc AAbbCc 0.5500 0.3162 
Aa BB cc AaBBcc 0.5500 0.3162 
AA Bb cc AABbcc 0.5500 0.3162 
aa bb CC aabbCC 0.7000 0.4642 
aa Bb Cc aaBbCc 0.7000 0.4642 
Aa bb Cc AabbCc 0.7000 0.4642 
aa BB cc aaBBcc 0.7000 0.4642 
Aa Bb cc AaBbcc 0.7000 0.4642 
AA bb cc AAbbcc 0.7000 0.4642 
aa bb Cc aabbCc 0.8500 0.6813 
aa Bb cc aaBbcc 0.8500 0.6813 
Aa bb cc Aabbcc 0.8500 0.6813 
aa bb cc aabbcc 1.0000 1.0000 
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CHAPTER III 
 
 
METHODS AND MATERIALS: SOFTWARE, CODING, & BENCHMARKS 
 
 
GenomeSIM: genome simulation software 
 In order to generate the simulated genomes for the study, genomeSIM was used 
[49].  This software package is able to simulate large scale datasets for either population 
or case/control whole-genome association studies.  GenomeSIM is written in ANSI-C++.  
User specified parameters can include the size of the population, number of genes, 
number of SNPs per gene, allele frequency ranges of non-causal SNPs, the minor allele 
frequencies (MAF) for single or multiple causal SNPs, and the penetrance function 
probabilities for the disease associated alleles.  A marked advantage in genomeSIM 
versus other genome simulation packages is that penetrance functions can be specified to 
a high degree of detail with multiple disease associated alleles to yield a variety of 
disease models.  Thus, a simple penetrance function with a single locus or more complex 
penetrance function incorporating multiple markers can be specified to generate 
dominant, recessive, additive, or multiplicative complex disease models.  Other 
simulation packages were also considered for generation of the datasets.  However, these 
simulators do not easily allow for multiple SNP penetrance functions, limiting their 
effectiveness for this particular study.  Given the nature of complex disease where several 
disease variants and the interactions between them determine disease status, genomeSIM 
was chosen.  Mainly for its flexibility in implementing common disease models with 
multiple disease associated alleles.  
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 There are two main modes of genomeSIM operation that allow for either 
population based or probability (case/control) based creation of datasets.  The probability 
mode was used for the creation of all genome datasets in this work to simulate a 
case/control study.  A 3 locus disease model was created and used for all the study 
evaluations.  Minor allele frequencies (MAF) of the 3 disease markers were given a fixed 
value of 0.20 (unless otherwise noted); while a range of allele frequencies for the non-
causal SNPs were specified from 0.01 to 0.50.  The simulator works by assigning disease 
status from the probabilities of the penetrance function tables.  At first, only the three 
disease associated marker alleles are generated, according to the fixed minor allele 
frequencies assigned by the user.  The user defined penetrance function for the genotype 
file is then looked up to assign disease or non-disease status based in the probability of 
disease for each genotype.  In its case/control generation mode, genomeSIM proceeds 
until the desired number of cases and controls are created having only the 3 disease loci.  
After this step, the remainder of the SNPs for each genome set is generated according to 
the ranges specified for non-causal SNPs.  For this study, all penetrance tables were 
either completely additive or completely multiplicative in nature.  However, genetic 
heterogeneity can be generated by genomeSIM by using multiple penetrance functions.  
This is done by assigning the number and percentage of different penetrance table models 
to use. 
 GenomeSIM uses a dual chromosome representation for the genotype data.  Thus, 
each individual in the population has two binary chromosomes. The allele frequency 
values are determined from either the specific allele frequencies for the disease-
associated alleles given by the user or sampled from the frequency ranges specified for 
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the non-associated alleles.  The genotype at any locus is represented as 0, 1, or 2 in the 
genomeSIM genotype output file.  This is determined by adding the allele “values” of the 
two chromosomes at each locus and corresponds to the wild-type homozygote of “AA” = 
0+0 = 0, a heterozygote with one disease associated SNP of “Aa” = 0+1 = 1, and a 
homozygous double mutant “aa” = 1+1 = 2.  
 
Benchmarks: genomeSIM 
 Given our study design incorporated association testing of many thousands of 
genotypes at the whole-genome scale, computational tractability is a primary concern.  
GenomeSIM was housed and run on the Vanderbilt ACCRE cluster using one Intel 
Opteron processor with 400MB of RAM.  According to the benchmarks in the 
publication of genomeSIM specifications, a 100,000 SNP dataset of 500 cases and 500 
controls took ~12 seconds and a 400,000 SNP set was produced in ~50 seconds [49].  
Our results show a longer creation time as a 10,000 SNP set of 500 cases and 500 
controls took ~15 seconds to create.  However, the 12 second benchmark for a 100,000 
SNP dataset was clocked on a different processor (Intel Xeon@ 3.06MHz) using 2GB of 
RAM.   
Our study used genotype file arrays for evaluation by either pooling or individual 
genotyping.  Each composite genotype file array created by genomeSIM consisted of 
10,000 SNPS for each of the 500 cases and 500 controls (sample size 1,000).  Overall, 
25,000 of these composite genotype arrays were created. This resulted in 25,000,000 
overall individual genotypes with 10,000 SNPs per genotype.  GenomeSIM is estimated 
to have taken ~104.16 hours or 4.34 CPU days to create the genotype files. 
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Converting genomesim genotype files to haploview format for individual association 
analysis: genomesim_2_haploview.m 
 The study was designed to use Haploview as the means of conducting individual 
genotype association testing. A MATLAB script was written in order to convert the 
genomeSIM genotype files into a Haploview compatible format. This conversion script, 
called “genomeSIM_2_haploview.m”, expands the SNP values from genomeSIM into a 
Haploview compatible version.  The main engine of the conversion script expands the 
single number allele representation of genomeSIM into a 2 number representation for 
each locus in the genotype file. This is done by essentially converting the homozygous 
wild-type “AA” genotype representation of [0] from genomeSIM to [1, 1] for Haploview.  
Likewise “Aa” and “aA” heterozygotes are converted from [1] in genomeSIM to [1, 2] or 
[2,1], respectively. An “aa” is converted from [2] in genomeSIM to [2, 2] for its 
Haploview representation.  A Haploview formatted file will contains six accessory 
information columns in addition to the 20,000 SNP marker columns, which is twice the 
number of SNPs due to the expansion from single to double binary representation for 
each locus.  In the Haploview compatible file, Column 1 contains the pedigree name.  
This is a unique identifier for this individual's family.  Column 2 is individual ID, here set 
to sample number 1 to 1000.  Columns 3 and 4 are father and mother ID, for trio and 
pedigree analysis, here they were all set to [0] as unknown.  Column 5 is sex, (1=male, 
2=female, 0=unknown), here all set to [0]. Column 6 is affection status, (1=control, 
2=case) determined from the original genomeSIM disease status column 1.  Columns 7 – 
20,007 are the marker genotypes.  Each marker is represented by two columns (one for 
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each allele, separated by a space).  A [0] in any of the marker genotype position indicates 
missing data or genotype error.   
 
Individual genotyping with haploview 
 For individual genotyping by association testing, Haploview analysis software 
was used [50].  Haploview is written in JAVA and conducts single point association 
analysis using the standard Pearson chi-squared test.  The chi-square derived p-values 
from the allele frequencies in case versus control individuals are the output of the 
association testing.  Further, permutation testing with the individual genotyping 
association test results can correct for multiple testing bias.  Additional features allow 
linkage disequilibrium (LD) measures such as D’, r2, and Log of Odds (LOD) to be 
calculated as well as haplotype block analysis, haplotype population frequency estimation 
[50].  For the purposes of this study, the single point association testing feature of 
Haploview served as a standard for individual genotyping for comparison of the pooled 
association testing by our pooled genotyping analysis tool (sm_PDA).  Although a GUI 
interface for Haploview is the default operating mode, the program was run in command 
line mode form the windows command line in order to speed up analysis and conduct 
individual genotyping association analysis in batch mode.  Memory use was doubled 
from the default 512MB to 1GB of RAM and resulted in a notable decrease in processing 
time.  Given that each dataset consisted of 1,000 cases and controls at 10,000 SNPs, and 
that there were 100 datasets each for as many as 15 parameter points, this modification 
became significant in terms of time savings.  Haploview took ~2 minutes to process each 
genotype file for each individual genotype.  
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 As a check for Haploview association testing for individual genotyping, our 
pooled analysis tool (sm_PDA) was used with a sampling error of 0% which 
approximates the association pooling statistic from Equation 1 to that of a chi-square 
distribution with 1 degree of freedom.  The association test statistic for pooled cases 
versus controls has two sources of variance in its denominator, measurement error (V1) 
and sampling error (V2) of Equation 1.   
 
Equation 1: Pooled genotyping association testing statistic 
     

 

 
 
 V1 is the variance due to measurement error and arises from the genotyping 
platform in the form of genotyping error.  This measurement error is present in both 
individual and pooled genotyping.  V2 in the pooled association testing is variance due to 
sampling error essentially form errors in allele frequency estimation by the genotyping 
platform and/or from unequal amounts of DNA comprising the pools.  Sampling error is 
not present in individual genotyping.  If the V2 sampling error is theoretically reduced to 
0%, then the only source of variance in the pooling statistic becomes measurement error 
(V1). Consequently, the pooling association testing statistic in Equation 1 approximates to 
a chi-square distribution with one degree of freedom.  This is what is used for individual 
genotyping by Haploview.  This served as a reciprocal check between Haploview and 
sm_PDA to insure that genotype files were being created, processed, and analyzed 
properly.   Additionally, as our modified version of PDA ran in ~2.3 seconds compared to 
Haploview taking ~2 minutes, a potentially useful by-product could be to use sm_PDA 
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for individual genotyping analysis.  Test value statistics using Haploview and sm_PDA 
on the same genotype files showed nearly identical chi-square derived p-values. 
 
Converting genomesim genotype files to pda format for pooled genotyping analysis:  
genomesim_2_pda.m 
 In our study, the Pooled DNA Analyzer (PDA) program was used to conduct 
pooled association testing [51].  The original PDA code was obtained from the 
developers.  We extensively modified the PDA by adding batch mode capability, re-
organizing the input and output results interfaces, and optimizing the source code 
resulting in a nearly 50-fold faster performance.  Our modified version of PDA was 
termed sm_PDA.  In order to convert a genomeSIM output genotype files to PDA 
compatible files, a MATLAB script termed “genomeSIM_2_PDA.m” was created.  This 
script scores the allele frequencies for each marker in the control and case groups. The 
output file is formatted as an sm_PDA compatible file.  For example, a genomeSIM 
genotype file is a [1,000 row by 10,001] column matrix where each row represents a case 
or control individual and columns represent the 10,000 SNPs plus 1 column for disease 
status.  The first column of to 10,001 total shows the disease state of the individual (0 for 
case, 1 for control) and columns 2 through 10,001 are the locus allele “values” of the 
binary chromosome (0, 1, or 2).  By convention, in a genomeSIM genome file, a locus 
with the genotype “AA” is scored as “0”, “Aa” or “aA” is “1”, and “aa” is “2”.  
genomeSIM_2_PDA.m converts the genomeSIM data into an allele frequency file 
suitable for sm_PDA.  This is done by scoring each genotype at each SNP and summing 
the frequencies of the normal “A” and disease associated “a” alleles.  
GenomeSIM_2_PDA.m scores the allele frequencies for the cases and controls of the 
32   
genotype dataset and lists them sequentially in the output file.  The result “PoolAF” file is 
a 20,002 row by 5 column matrix of allele frequencies along with other information.  The 
first column is disease status, 1 for controls and 2 for cases.  The second column lists the 
marker “name”, in our case the marker number. The third column is the total number of 
cases or controls in the dataset. The forth column is the major allele frequency.  The fifth 
column is the minor allele frequency (MAF).  The major and minor allele frequencies are 
scored by expanding each locus “score” form genomeSIM file into an allele frequency 
matrix.  An “AA” homozygous wild-type with no disease allele variants is represented by 
a [0] in the genomeSIM datafile.  GenomeSIM_2_PDA.m will add 2 to the “wild-type” 
signifying the presence of two wild-type alleles at this SNP locus.  A heterozygous “Aa” 
or “aA” represented as [1] in the genomeSIM file will add 1 to the “A” array element and 
1 to the “a” element of the allele frequency matrix, signifying one normal allele and one 
disease associated variant allele are present at that locus.  It follows that a homozygous 
double mutant “aa” which is [2] in the genomeSIM file will add 2 to the “a” element of 
the array at its corresponding locus, thus representing the presence of 2 disease alleles at 
that locus.  This is processing step connects the genomeSIM genotype file output by 
transforming it into PDA formatted allele frequency file for subsequent pooled 
association analysis. 
 
Benchmarks: genomesim_2_pda 
 Using the PROFILER function of MATLAB, the total time required to convert a 
genomeSIM genotype file to a PDA compatible format was evaluated.  A genomeSIM 
file containing 10,000 SNPs for 500 case and 500 control individuals took 19.5 seconds 
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to convert.  The genomeSIM_2_PDA conversion script has three main sections.  It first 
loads the genomeSIM genotype text file into active memory as matrix.  Second, the 
genotype matrix is passed to the scoring function with a function call to the calculation 
function.  Third, the scored pooled allele frequencies are written as a delimited text file 
using the MATLAB DLMWRITE function.  Looking at the time breakdowns for each 
function within the automated conversion script, 70% of the total time (13.7 of 19.5 total 
seconds) is spent opening the genomeSIM genotype text file.  The second most time 
consuming part of the script is the allele scoring function itself, which takes 4.1 of the 
total 19.5 seconds, corresponding to 21% of the total time.  Thirdly, the writing of the 
allele frequency results to a tab delimited file using DLMWRITE takes 1.7 seconds, 8.8% 
of the total time.  Overall, the 25,000 genotype files analyzed for the study are estimated 
to have taken 135.4 CPU hours or 5.6 CPU days to pre-process from the genomeSIM 
genotype files to PDA compatible input files.  Note that this pre-processing step is 
significantly longer than the actual pooled association testing analysis by sm_PDA, 
which takes ~2 - 2.5 seconds per file, estimated at 16.56 days 0.69 CPU days overall for 
the 25,000 genotype files tested.  
 
Creation of sm_PDA by modifications to PDA (the pooled dna analyzer) for pooled 
association analysis:  
 In order to conduct pooled genotyping associating analysis a modified version of 
the Pooled DNA Analyzer (PDA) program was created [51].  The PDA is a MATLAB 
implemented suite of modules which allows single point association testing of pooled 
DNA using the pooled association testing statistic (Equation 1). Additional functionality 
allows for chromosome-wide multipoint association tests based on p-value combinations 
34   
using a sliding-window concept.  Although PDA is designed primarily for pooled 
associational analysis, individual genotyping can also be conducted by either single point 
or multipoint test by setting the sample error to 0%, effectively decomposing the pooling 
association test statistic into a chi-square test with 1 degree of freedom, which is what is 
used for individual genotyping.  This feature of PDA was used as a double-check for the 
individual genotyping conducted by Haploview, as well as a check to confirm that the 
creation and processing of the pooled allele frequency files was performed correctly by 
correlating the Haploview individual genotyping with the PDA “individual” genotyping 
results.  Additionally, after the original version of PDA was modified into sm_PDA, 
individual genotyping with sm_PDa could be run at a 50-fold reduced time.   
 The original version of the Pooled DNA Analyzer (PDA) implements a GUI 
where the user directs a path to a folder containing 3 necessary files to run a pooled 
association analysis.  The first of these 3 files is a column vector with the designated 
names or number of each marker, termed “SNPname”.  The second file used by PDA is 
“IndPI” and is the basis for signal correction and normalization for the association 
testing.  The “IndPI” (Individual Peak Intensity) file is a four column matrix which 
contains the SNP name, its map location (optional), and relative signal intensities for 
homozygous and heterozygous individuals at each SNP.  Its purpose is to normalize the 
signal intensities of the allele variants at each genotyping feature of the genotyping 
platform.  The purpose of this file is to reduce sampling error in pooling by correcting 
biased signal intensities or platform artifacts which are a major source of allele frequency 
estimate error.  For our study, all peak intensities of the “IndPI” file were defaulted to 1. 
In practice, databases exist in which known heterozygote and homozygote intensities of 
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the SNPs are cataloged and serve as a reference for normalization and correction [7, 52, 
53].  The third and most directly evident file needed for PDA is the “PoolAF” (Pooled 
Allele Frequencies) file which contains major and minor allele frequencies of the case 
and control groups.  The “PoolAF” file consists of the disease or group identifier (1=case, 
0=control), the SNP name (matching the “SNPname” file), the number of individuals in 
each pooled group (number of cases or number of controls), and the allele frequencies for 
the major and minor alleles at each locus.  These three PDA processing files need to be 
located in the same folder, which can be specified by the user from the PDA GUI. 
 The PDA GUI has eight edit boxes and over 20 check boxes which are used to set 
the parameters for pooled association testing, shown in Figure 3. 
  
 Figure 3: Pooled DNA Analyzer GUI screen 
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 There are seven parameter fields in the PDA GUI which are combinations of edit 
and check boxes. The parameter fields are: 
1) Edit boxes for the input and output path directories,  
2) Check boxes for the number of groups in the study, (one group or two) and check 
boxes to assume a constant Coefficient of Preferential Amplification (CPA) 
between the groups if a two group study.   
For this study, a two group test for cases and controls with constant CPA assumed.   
3) Check boxes for the method of peak signal normalization.  Either using the 
Coefficient of Preferential Amplification (CPA) method [51] or the raw peak 
intensity.  
For this study, raw peak intensity was used with both the homozygote and 
heterozygote intensities defaulted to 1.  
4) Check box to calculate the standard error and the number of bootstraps to use. 
For this study, 500 bootstraps were used.  
5) Check box to calculate the estimate of allele frequency.   
Checked to “yes” in the study.  
6) Check box to perform the single point association test and the sample error to 
incorporate.   
This is the main functionality to perform pooled association analysis.  Sample error 
was specified from 0% to 5%.  
7) Multiple check boxes and edit fields to perform multi-point association testing. 
• Whether to use p-values from single point association or peak intensities. 
• Whether map information is present. 
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• The weight functions for peak intensities. 
• A threshold value for truncation. 
• The number of Monte Carlo simulations to use for permutation testing. 
• The window size to use for multipoint testing. 
• The disease model effect to use for the SWEPT multipoint test: 
multiplicative, additive, or minimal.  
 
 In order to evaluate the time profile characteristics of the Pooled DNA Analyzer 
(PDA), the MATLAB PROFILER was used.  The PROFILE function of MATLAB 
analyzes the amount of time spent on the execution of functions within a MATLAB 
script.  Using the PROFILE VIEWER mode in MATLAB, the results are output as an 
HTML file.  The PROFILER can output the time in seconds as well as percent of total 
time spent in each line or function of a script.  It also has a feature which details the 
clocked times between parent and child functions (additional functions called from the 
parent).  Additionally, the number of times a function is called are also listed.  
The original PDA code was run over a dozen times using the PROFILER function 
in order to clock its speed and the time distributions of the various blocks of code.  The 
results of a representative PDA run time profile are shown in Figure 4. 
 
  
 Figure 4: MATLAB PROFILER for PDA.
 results for time to run original PDA code @ 112 seconds and percent of time spent in 
function calls: 
 
 
  
39   
 
 
40   
 Results from the time analysis show that the original version of PDA took 110-
120 seconds to analyze a pooled genotype file.  Given that the project would need to 
process over 25,000 genotype files, using the original version of PDA would take more 
than 50,000 minutes, or 34.722 days of CPU time to calculate association analysis for the 
pooled genotypes.  In addition to the slow processing time, the original PDA did not have 
batch capability and was not automated by any definition of the word.  For this reason, a 
speed enhanced version of PDA (sm_PDA) was created which would have a batch 
operation mode as well as reduce the time to process a pooled genotype file for 
association testing.  
 
SM_PDA: added batch processing and automation to the original PDA 
 One of the main reasons for modifying the original version of PDA into sm_PDA 
was to add batch mode functionality, allowing for association analysis of the datasets in 
an automated fashion.  As the project involved association analysis and genotyping of 
tens of thousands of genotype files by pooled allelotyping, this automation and batch 
mode functionality were critical.  In order to conduct a pooled analysis with the original 
version of PDA, the pooled allele frequency files (“PoolAF” files) generated form 
genomeSIM_2_PDA.m would need to be moved into the PDA input directory folder one 
at a time. Then the user would hit the “APPLY” button in the PDA GUI to perform 
association analysis.  Once the pooled analysis was completed, the results file would have 
to be moved to another folder to avoid being overwritten by the next analysis.  This 
process would need to be repeated for each genotype file and was thus not feasible for the 
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more than 25,000,000 genotypes which were analyzed in the pooled genotyping phase of 
the study.  
 Batch modifications to the original PDA code allowed for processing the 
thousands of genotype files in each phase of the pooled analysis to be analyzed without 
manually setting up and moving each file for processing by PDA.  This allowed for a 
major improvement in automation of the program as well as reduced time to process the 
association testing.  The basic procedure for batch mode operations was to enclose the 
single and multipoint testing processes within a three nested FOR_LOOP structure.  In 
order to use the FOR_LOOP syntax, the pooled allele frequency file input name 
parameter in the original PDA was modified to accept user specified file names (instead 
of only “PoolAF”) using the SPRINTF and EVAL functions of MATLAB.  For example, 
a round of genotype files created in genomeSIM would have 100 replicates for a given 
disease model at a given relative risk.  Using the genomeSIM_2_PDA.m script, each of 
these genotype files would be converted to a Pooled Allele Frequency file with appended 
alphanumeric tags; “PoolAF_α_β_γ_δ". The first filename modifier (α) was the sub 
study being done such as relative risk, genotype error rate, or population size.  The 
second filename modifier (β) is the disease model of the genotype simulation, “add” for 
additive or “multi” for multiplicative models.  The third appended tag (γ) is replicate 
number as 100 replicates were done for each data point.  In general, multiple 
alphanumeric tags were appended to the “PoolAF” files during their creation from the 
original genomeSIM genotype data.  Upon pooled genotyping analysis with sm_PDA, the 
SPRINTF and EVAL functions of MATLAB were used in order to process the 
“PoolAF_α_β_γ” files into application memory in an automated batch mode.  Using this 
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modification, the “PoolAF_α_β_γ” file could be referenced by the correlated 
FOR_LOOP iteration parameters.  The overall result was an automated process which did 
not require moving individual “PoolAF” pooled allele frequency files into the input 
folder one at a time as in the original PDA.  Further, the pooled association testing result 
files did not need to be moved out of the results folder in order to avoid being overwritten 
by the subsequent results file.  This was among the most significant modification made in 
the creation of sm_PDA and represented the added functionality of an automated 
program with true batch mode capability, something that the original PDA was not able 
to do. 
 
SM_PDA: logical operator modifications 
 In the MATLAB code for the PDA, the GUI implemented check boxes and edit 
boxes are coded into logical conditions that set the parameters for association analysis.  
In the original PDA code, the logical checks are written in a way that evaluates the entire 
logical expression and then returns the result.  If the logical expressions are long, than 
evaluation of the entire expression may not be necessary, and could become time 
consuming and inefficient.  For example, any “false” element of a logical expression 
connected with “and” will result in a “false” evaluation of the entire expression.  If the 
“false” element occurs during evaluation of the expression, checking the remaining 
elements is not necessary in this case.  The many hundreds of logical conditions form the 
original PDA code were re-coded using “short circuit” logical connectors in order to 
eliminate unnecessary checks.  For example, the first logical evaluation line of the 
original PDA processing script is shown in Box 1. 
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Box 1: original version of pda logical expression syntax for 
check box evaluation:  
 
 if check1==1 & check2==1 & check5==1 & check7==1 & check9==1 &   
     check11==1 & check12==1 & check14==1 & check16==1; 
 
 
 
 The “&” is the logical operator “and” in MATLAB and the line is a logical 
expression with eight conditional checks all connected by the logical “and” operator.  For 
this statement to be true, all of the conditionals must be true.  If any single conditional is 
false, then the entire statement is evaluated as false.  With this statement syntax as it is 
written in the original code, each element of the entire expression is evaluated first, and 
then the logical value of true of false is assigned to the statement as a whole.  This is a 
potentially wasteful exercise if, for example, the first “check” is false.  This renders the 
entire expression as false, yet all of the remaining checks will be evaluated.  The short 
circuit “and”, coded in MATLAB as “&&”, was used in these logical statements in order 
to speed up the code.  In this syntax, each element of the expression is evaluated and, as 
soon as one element is false, the expression returns false without any further element 
evaluations.  Likewise, the logical “or” was replaced with “short circuit or” which will 
return “true” if any of the elements are true and will not evaluate the expression further.  
Given this change, all of the logical expressions should be evaluated with the fewest 
possible number of elements being evaluated.  Although logical expressions are relatively 
quickly evaluated in MATLAB, given the fact that there are nearly 100 potential logical 
evaluations for each genotype file tested, and 25,000 association tests files are evaluated 
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in this study, the time savings are potentially significant.  Overall reduction with 
implementation of the logical short circuit operators, in part, contributed to a speed up in 
the association testing calculations of at least 4 fold.  The original PDA was clocked at 
9.6 seconds for that section of the program code to run, while the entire modified 
sm_PDA code ran in 2.3. 
 
SM_PDA: result output file modifications 
 Another modification to the original PDA program made in order to optimize and 
automate the process was to change the formatting and writing characteristics of the 
association testing result files.  In the original version of PDA, the results were written to 
a log file in “real-time”.  Specifically, the association statistics of each marker were 
written to the log file as soon as the association processing was done for each marker.  
This mixing of association test processing with input/output transitions for writing to the 
results file is extremely inefficient.  Significant time could be and was saved by 
performing all of the processing of the association testing first, storing the final results in 
a matrix or application memory, and only then writing to an output file.  Additionally, 
input/output transitions which updated the progress of PDA to the console after the 
processing of every SNP, every bootstrap, and each function module were eliminated.  
The original version of PDA used FPRINTF statements to write the output results to a log 
file.  The FPRINTF function writes formatted data and (in the original version of PDA) 
writes each line of association testing results as they are calculated.  This was changed in 
sm_PDA by using the DLMWRITE function which is faster, albeit less versatile, than 
FPRINTF.  Sm_PDA saves the pooled association testing results as a matrix during the 
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calculations and writes them as a delimited text file only when all the association testing 
is completed.  According to the MATLAB designers, DMLWRITE is a faster function 
than FPRINTF, but the major time savings with this modification are a result of 
eliminating the writing of each line of results to both the log file and the console as they 
are calculated from the association testing. 
 Sm_PDA outputs tab delimited text file containing the marker number, the pooled 
association testing chi-square value, and the chi-square correlated p-value.  Results of the 
PDA modifications into sm_PDA are a nearly 50-fold reduction in pooled association 
analysis.  These time analysis comparison results are shown in detailed in 
BENCHMARKS: OriginalPDA and speed modified sm_PDA.  
 
Benchmarks: original PDA and speed modified SM_PDA 
 The original version of PDA was evaluated for its time to process a pooled allele 
frequency file using the MATLAB PROFILER.  The total time for evaluating one 
genome file was >110 seconds.  Using the PROFILE function, it was shown that the 
majority of CPU time was used for real time progress messages sent to the MATLAB 
console window of the standard output (i.e. monitor) and creation of the results logfile as 
shown in Figure 4. 
 
 In total, over 90% of the CPU time was used for two tasks related to outputting 
results.  83% of the total CPU time (93 of 112 seconds) was used for progress updates 
during the Bootstrapping stage to determine the chi-square p-values of association 
testing.  The second most time consuming task was opening, writing to, and closing the 
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log file output of the association analysis.  This results log process used 4.9 seconds or 
4.4 % of the total time to open and close the log file 10,000 times (once for each marker), 
and 4.4 seconds or 3.9% of the total time writing the associating results to the log file.  
Adding up the log file open/close and writing results and progress to the console and 
output log showed that over 91.6% of the total time by the original PDA code was used 
there.  Note that none of the association testing was done in these steps, only the output 
writing.  Thus, the time involved in actual association testing using the Pooled DNA 
Analyzer (PDA) software is not the most time consuming step at all, surprisingly.  All 
remaining tasks, including the association analysis itself were performed in the remaining 
9.6 seconds or 8.4% of the total 112 seconds.  Calculating for the original PDA version, 
25,000 genotype files times 112 seconds each yields 777 CPU hours or 32.4 days of total 
CPU time that would have been required for pooled analysis had sm_PDA not been 
created and used.   
 A MATLAB PROFILER time analysis of the modified version, sm_PDA is 
shown in Figure 5.   The figure is representative of over a dozen runs of sm_PDA with 
time clocking from the PROFILER. 
   
 Figure 5: CPU time for sm_PDA.
MATLAB PROFILER results for time to run the modified sm_PDA code @ 2.3 seconds 
compared to 112 seconds for the original PDA (
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Figure 4). 
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 Overall time for sm_PDA is 2.3 seconds compared to 112 seconds for the original 
PDA version.  The total CPU time for processing the 25,000 genotype files was estimated 
to be 16.66 CPU hours or 0.69 CPU days to process.  Thus, with modified sm_PDA, the 
total time to process the 25,000 genotype files is decreased by a factor of 46 fold 
compared to the original PDA.  The overall time reduction for processing the pooled 
genotype files was reduced from 32.4 CPU days for the original PDA to 0.69 CPU days 
for sm_PDA.  More importantly than the time savings from speed optimizations, 
sm_PDA added a batch mode functionality which was critical in allowing the 25,000 
pooled genotype files to be analyzed in an automated process. 
 
Parsing the results from pooled and individual association analysis: pda_2_pval.m 
and haploview_2_pval.m 
 Once the sm_PDA processed the pooled genotype files, 100 association analysis 
test result replicates per data point were produced.  In order to combine the overall results 
from the pooled association tests, a MATLAB script termed “PDA_2_pval.m” was 
created.  The function of this script is to combine the results of the repetitions of the 
sm_PDA association testing and determine the average the p-values for the causal SNPs 
from the association analysis.  Additionally, the standard deviations were calculated 
using the MATLAB STANDARD function.  The standard deviation can be used along 
with the number of genotype file repetitions in order to derive the confidence intervals. 
 The PDA_2_pval.m script functions by first loading the 100 sm_PDA pooled 
association test results files for each repetition set.  The results are loaded into a matrix 
and then sorted by chi-square p-value.  The p-values of the 3 disease associated SNPs are 
averaged over the one hundred genotype repetitions as well as their respective average 
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ranks.  Additionally, the standard deviations of the causal SNP p-values over the 
replicates are calculated.  These results are output into two files, one listing the average 
p-values, and the second listing the standard deviations of the p-values.  A similar 
MATLAB script, “Haploview_2_pval.m”, parses the association testing results from 
Haploview individual genotyping.  The Haploview_2_pval.m script parses the chi-square 
derived p-values, and averages them for the 100 replicates per data point.  The average 
rank and standard deviations of p-values over the 100 replicates for each data point are 
also calculated. 
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CHAPTER IV 
 
 
RESULTS 
 
 
Results: sample size 
 The sample size in the association study and the ability to identify the causal 
variant alleles given the sample size was evaluated for pooled versus individual 
genotyping.  GeneomSIM was used in its probability mode to create a case / control 
populations from 200 to 1,000 individuals.  GenomeSIM assigns disease status to each 
individual in the population as their genotype is generated.  In the population mode of 
genomeSIM, this disease status assignment will continue until the specified numbers of 
cases and controls are generated.  The genomeSIM input parameter files were constructed 
to output datasets with varying populations from 100 to 500 disease cases (in increments 
of 100) and an equal number of controls.  This yielded 5 populations of 200 to 1000 
(incremented by 200) comprised of equal numbers of case and controls for comparison 
by pooled allelotyping and individual genotyping.   These populations were generated for 
three levels relative risk; 1.5, 2.0, and 2.5 using Penetrance Tables 4, 7, and 10, 
respectively.  Finally, additive and multiplicative models were both used to generate the 
populations. 
 The genotype files were generated on the VANDERBILT Advanced Computing 
Center for Research & Education (ACCRE) cluster using an Intel Opteron processor with 
400MB of RAM.  For this study of the effect of sample size on individual genotyping 
versus pooling, 3,000 total genotype files were generated; 100 replicates for 5 sample 
size populations at 3 relative risks levels and 2 complex disease models. 
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The genomeSIM genotype files were converted by the genomeSIM_2_PDA.m 
pre-processing script for pooled genotyping with sm_PDA.  The pooled genotype files 
were then processed by sm_PDA with a 2% sample error rate.  The results were parsed 
by PDA_2_pval.m and chi-square p-values of the causal SNPs were obtained.  The 
averaged p-values for the 100 replicated of each data point were obtained. 
 In parallel the genomeSIM genotype files were also converted to Haploview 
compatible files for individual genotyping with genomeSIM_2_Haploview.m.  The 
individual genotyping results were parsed from the Haploview association testing result 
files with Haploview_2_pval.m. 
 The results of the pooled allelotyping with 2% sampling error were compared to 
the individual genotyping.  Significance level was set to p-value <5e-2.  The average chi-
square p-value for 100 replicate genotype files versus the number of cases and controls 
for additive and multiplicative disease models at three relative risks (1.5, 2.0, and 2.5) 
were graphed.  These results are shown in Figure 6.  
  
 Figure 6: Effect of Smaple size on pooling versus individual 
genotyping 
Individual genotyping: white squares with black lines
Pooled genotyping with 2% sampling error: red circles with red line
Cutoff threshold (p-value = 5e
 
Data points represent average p
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 The results show that for the multiplicative model with a relative risk of 1.5, 
neither pooled (Figure 6: red lines with circles) nor individual genotyping (Figure 6: 
black lines with squares) was able to identify any of the 3 causal SNPs with a p-value 
above the threshold of 5e-2 for all population sizes tested (Figure 6: upper left panel).  At 
relative risk of 2.0, the three causal SNPs were identified with a population of 400 cases 
and 400 controls, while the pooled genotyping for the multiplicative model at relative risk 
2.0 did not identify any of the causal SNPs, even up to 500 cases and 500 controls 
(Figure 6: upper middle panel).  At a relative risk of 2.5, the individual association 
analysis crossed the 5e-2 p-value threshold identifying the 3 causal SNPs with 200 cases 
and 200 controls, while pooled genotyping identified 1 of the causal SNPs with 200 cases 
and controls and all 3 SNPs at 300 cases and 300 controls (Figure 6: upper right panel).   
 For the additive model, 2 of the 3 disease associated SNPs were identified at 
relative risk 1.5 with individual genotyping of 400 cases and 400 controls, and all 3 
markers were identified with 500 cases and 500 controls.  Results for pooled genotyping 
additive model at relative risk 1.5 show that none of the populations tested yielded p-
values above threshold (Figure 6: lower left panel).  For relative risk 2.0, individual 
genotyping with 200 cases was sufficient to identify all 3 disease SNPs while pooled 
genotyping identified 1 of the causal SNPs with 200 cases and all 3 causal SNPs with 300 
cases and 300 controls (Figure 6: lower middle panel).  For relative risk 2.5, individual 
genotyping was able to identify 1 causal with 100 cases and all 3 with 200 cases while 
pooling identified all 3 causal SNPs with 200 individuals. (Figure 6: lower left panel) 
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Results: relative risk 
 In order to evaluate the resolution of pooling and individual genotyping over 
varying relative risks, genomeSIM was used to create genotypes with a range of relative 
risks.  The relative ranges varied from 1.07 for a single disease associated to 1.5 for the 
corresponding 6 variant genotypes in the least penetrant model (Penetrance Table 1) ; up 
to 2.5 for a single disease associated and 10.0 for the corresponding 6 variant genotypes 
variant (Penetrance Table 10) (see Penetrance Tables 1-10).  The relative risks were 
tabulated in the penetrance tables for both additive and multiplicative models.  A total of 
20 penetrance tables were constructed; 10 for the additive complex disease model and 10 
for the multiplicative model.  The baseline disease probability was set to 10% for all 
penetrance functions.  This 10% baseline represents the probability of disease given no 
disease associated alleles.  This 10% baseline accounts for non-genetic factors such as 
environmental conditions (phenocopy) which contribute to disease status and reflects a 
more realistic complex disease model as environmental factors significantly contribute to 
complex disease.  Additionally, the base rate of 10% includes disease associated alleles 
which may not be present on the SNP chip and other non-genetic entities which 
contribute to disease progression. 
 Relative risk is defined as the ratio of the probability of disease given the 
case/disease genotype versus the probability of disease given the control/normal group 
genotype.  For example, given a baseline of 10% risk of disease in the control group, if 
the probability of disease in the case group is 20%, then the resulting relative risk is 2.0, 
[(0.20 / 0.10)].  Therefore, the case group is twice as likely to have the disease compared 
to the control group.  The penetrance functions in genomeSIM were constructed using the 
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Risch and Teng complex disease model formulas as a foundation [48] (see Methods and 
Materials: Complex Disease Model Construction).  The “AABBCC” genotype represents 
the non-disease control for the three gene model with 6 wild-type, non-disease associated 
alleles.  The probability of disease for the control genotype is set to 10% to allow for 
phenocopy.  In the complex disease model formula, this genotype and its associated 
penetrance probability is represented as f0.  The penetrance values for the model 
genotypes were calculated using an expansion of the additive and multiplicative model 
formulas (Equations 2 and 5).  The f0 corresponds to the wild-type genotype of 
“AABBCC” in which there are no disease associated alleles present in the diploid 
genotype and its resulting probability.  The penetrance probability for the f0 is set in this 
baseline state as 0.10 to account for phenocopy and other non-genetic factors.  The f1 for 
the expanded 3 marker model concatenates three analogous f1 for each locus “Aa”, “Bb’, 
and “Cc”.  Thus, the genotype “AaBbCc” represents the f1 for the 3 locus model.  It 
follows that the f2 is represented by the “aabbcc” genotype to represent 6 disease 
associated alleles; the 3 markers with 2 disease associated alleles each.  Expanding the 
formula proposed by Risch and Teng for complex disease models resulted in an increase 
from 3 possible genetic states (31 for a single gene model) in the original model to 27 
possible genetic sates (33) with a 3 locus model. 
 The penetrance functions were calculated by setting the probability of the f0 to 
0.10 and varying the probability of the f2; from [0.15, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 
and 1.0].  The expanded model formulas were then used to determine the penetrance 
probabilities for the intermittent genotypes including the f1 as well and the remaining 24 
genotype states (see Penetrance Tables 1-10).  By convention, the penetrance functions 
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were labeled by the relative risk of 1 disease associated allele being present versus the f0 
with no disease associated alleles.  For example, if the f0 = [“AABBCC” with penetrance 
probability of 0.10], the f2 = [“aabbcc” with a penetrance probability of 1.0], then the 
penetrance probability of 1 disease associated allele is 0.25, calculated by Equation 4.   
 
Equation 4: General penetrance probability calculation for additive 
complex disease model  
 
f = [ f0 +' 
 

(] * (number of disease associated alleles) 
 
 The relative risk of the single disease associated allele relative to the f0 is (0.25 / 
0.1) = 2.5.  Thus, the penetrance function for the additive disease model having f0 = 0.1 
and f2 = 1.0 has a relative risk of 2.5 for a single disease associated allele being present.  
This penetrance function was labeled as “penetrance table with relative risk 2.5” for 
reference.  The penetrance function of the corresponding multiplicative model having f0 
= 0.1 and f2 = 1.0 was also designated as relative risk 2.5.  However, a single disease 
associated allele in this multiplicative model will not result in a relative risk of 2.5 as 
does the additive model with the same f0 and f2 parameters.  The beginning and end 
points are equivalent in terms of penetrance probability.  This naming convention allows 
for comparison between the additive and multiplicative models. 
 For the additive and multiplicative models of complex disease, GenomeSIM was 
used to create 100 replicates for each of the 10 relative risk points [1.08, 1.16, 1.33, 1.5, 
1.66, 1.83, 2.0, 2.16, 2.33, and 2.5]. A total of 2,000 genotype files were created and 
subsequently analyzed.  Each genotype file was of 10,000 SNPs for 500 cases and 500 
controls.   The genomeSIM files were converted to PDA and HAPLOVIEW compatible 
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genotype files by GenomeSIM_2_PDA.m or GenomeSIM_2_HAPLOVIEW.m scripts, 
respectively.  The converted genotype files were processed by sm_PDA with a 2% 
sampling error rate for the pooled genotyping and HAPLOVIEW, for individual 
genotyping.  The results were parsed by PDA_2_PVAL.m or Haploview_2_PVAL.m.  
The average chi square p-value of the 100 individual or pooled genotypes was plotted 
versus the relative risk.  These results are shown in Figures 7 and 8. 
  
58   
 
 
 
Figure 7: Individual versus Pooled genotyping at varying relative risk 
ranges 
 
Individual genotyping: white squares with black lines:  
Pooled genotyping with 2% sampling error: red circles with red line.   
Cutoff threshold (p-value = 5e-2): blue horizontal line  
 
Data points represent average p-value of 100 simulations 
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Figure 8: Individual versus Pooled genotyping for a Multiplicative 
Model of complex disease 
 
Individual genotyping: white squares with black lines:  
Pooled genotyping with 2% sampling error: red circles with red line.   
Cutoff threshold (p-value = 5e-2): blue horizontal line  
 
Data points represent average p-value of 100 simulations 
 
  
1.E-06
1.E-05
1.E-04
1.E-03
1.E-02
1.E-01
1.
33
1.
50
1.
66
1.
83
2.
00
2.
16
2.
33
2.
50
Ch
i2
P-
v
al
u
e
Relative risk
60   
 For the additive model, individual genotyping was able to detect all 3 causal 
SNPs above threshold (<5e-2) at a minimum relative risk of 1.5.  The results for pooling 
with a 2% sampling error rate showed that the 3 disease associated alleles were detected 
above threshold at a minimum relative risk of 1.83 (Figure 7).  For multiplicative model, 
individual genotyping was able to detect 2 of the 3 causal SNPs at a relative risk of 1.66, 
and all 3 causal alleles at a relative risk of 1.83.  For pooled genotyping with a 
multiplicative model, 2 of the 3 causal SNPs were detected at a relative risk of 2.33, and 
all 3 disease variant markers were detected at relative risk 2.5 (Figure 8).  The gap in 
detection resolution between pooling and individual genotyping (with respect to relative 
risk) was wider in the multiplicative model compared to the additive model.  The 
detection level of the 3 disease associated alleles in the additive model was relative risk 
1.5 for individual genotyping and 1.83 for pooling. This yielded a minimum relative risk 
differential of 0.33 relative risk units for the pooling to detect the 3 causal SNPs.  This 
differential was wider in the multiplicative model.  Individual genotyping resolved the 3 
causal SNPs at a relative risk of 1.83, while pooling resolved at a relative risk of 2.5, a 
difference of 0.67 relative risk units.  Thus the gap of the relative risk at which individual 
genotyping and pooled genotyping are able to resolve the disease associated alleles is 
twice as large for the multiplicative model (0.67 relative risk) versus the additive model 
(0.33 relative risk). The conclusion from the data suggests that the multiplicative model 
of complex disease requires a higher level of relative risk conferred by the disease 
associated alleles for detection compared to the additive model.  This was true for both 
individual and pooled genotyping, but more pronounced in pooling.  These results further 
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suggest that complex diseases with an additive characteristic of disease penetrance are 
more amenable to a pooling approach.  
 
Results: genotyping error 
 In order to evaluate the effects of genotype error on pooled and individual 
genotyping, GenomeSIM was used to create files with 10,000 SNPs and 1,000 samples in 
the population (500 cases and 500 controls).  Genotype error was incorporated at levels 
of ranging from 0% to 10%, with 1% increments.  In terms of the simulations, genotype 
error is a parameter which can be specified during the creation of the genotypes and is 
derived by inserting an “unknown” call at a marker position to simulate a genotyping 
error from the genotyping platform.  The marker position at which the “unknown” call is 
located is based upon a uniform random distribution and the user defined percentage of 
genotype error.  As each locus is assigned a value during the creation of the genotype, a 
random number is generated from a uniform distribution and checked against the 
percentage of genotype error specified in the genomeSIM parameter input file.  The 
“unknown” flag representing a genotype error is inserted based upon this process and 
inserted if the sampled number is below the threshold set for the genotype error.  
 GenomeSIM was used to create 100 replicates of genotype files with 11 levels of 
genotype error ranging from 0% to 10% (with 1% increments).  This yielded 1,100 
genotype files in total for the genotype error evaluation.  The additive model penetrance 
function in Penetrance Table 7 was used for the creation of the simulated genotypes.  The 
relative risk of a single disease variant allele from Penetrance Table 7 is 2.0; meaning that 
the presence of a single disease associated allele raises the probability of disease from 
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0.10 to 0.20.  Additional mutations will contribute in a purely additive manner, thus 2 
mutations have a relative risk of 3.0; 3 mutations will have a relative risk of 4.0; and 6 
mutations result in a relative risk of 7.0.  This penetrance function was chosen based on 
the results of the relative risk evaluation in which both individual and pooled genotyping 
were able to detect all 3 disease associated alleles with a chi-square p-value <5e-2 at 
relative risk of 2.0 (Figure 7).  This relative risk level was also chosen because it is 
among the first levels of relative risk at which both individual and pooled genotyping 
results were in excess of the p-value threshold of 5e-2.  Therefore, this level of relative 
risk would be among the most vulnerable to having it p-values fall below the significance 
threshold.  The results from the genotype error study are shown in Figure 9. 
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Figure 9: Effect of Genotype Error on Individual and Pooled 
Genotyping: 
 
 
Datapoints are average p-values of 100 simulations 
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 Individual genotyping at 0% genotype error had p-values of [1.5e-4, 2.4e-4, and 
5.0e 4] for the 3 associated SNPs (averaged over the 100 repetitions).  At 10% genotyping 
error, the p-values are [6.6e-4, 1.1e-3, and 1.0e-3].  Although there is a noticeable decline 
in the significance of the p-values, it is less than an order of magnitude and well above 
threshold cutoff of <5e-2.  This was also the case for all levels of genotype error tested in 
the intermittent values of 1%-9% genotype error.  Overall, genotype error up to and 
including 10% lowered the significance of the individual genotyping p-values by less 
than one order of magnitude compared to perfect genotyping with 0% error.  
 Pooled genotyping was tested at levels of genotyping error from 0% to 10%, with 
1% increments.  Additionally, sampling errors from 0% to 5% (with 1% increments) 
were used for pooled genotyping in order to determine the effects of genotyping error in 
combination with varying levels of sampling error.  Pooled genotyping with 0% sampling 
error represents a theoretical baseline control as the association testing statistic reduces to 
a chi-square test when the variance form sampling error is 0% (Equation 1).  As such, 
pooled genotyping with a 0% sampling error will have nearly identical statistical results 
as individual genotyping.  This was the case in the genotyping error evaluation as pooling 
with 0% sampling error had the same p-values as individual genotyping.   
At all levels of pooled genotyping tested (with sampling error 1% to 5%), the 
decreased significance of p-values was much less than one order of magnitude (Figure 9).   
In fact, the level of sampling error in pooled genotyping was much more of a factor in 
overall effect on the p-values and dominated the effect of genotyping error at all levels 
tested.  Pooled genotyping with a 0% genotyping error and a 1% sampling error rate had 
less significant p-values than individual genotyping with a 10% genotyping error rate.  
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Further, even a 1% percent increase of sampling error in pooled genotyping lowered the 
significance of p-values more than a 10% increase in genotyping error.  For example, an 
increase of sampling error from 1% to 2% is more detrimental to the results of pooled 
genotyping than an increase on genotyping error from 0% to 10% within the same 
sampling error percent. 
 
Results: pooling specific errors: allele frequency measurement error and sample 
mixing error 
In order to evaluate the effect of sample mixing and allele frequency measurement 
error on pooled genotyping, GenomeSIM was used to create genotype files having 10,000 
SNPs for 500 case and 500 controls at varying relative risk levels.  An additive complex 
disease model was employed for the sampling error analysis study.  Using Penetrance 
Tables 1-10, additive common disease models having each of the 10 relative risk range 
levels were used.  These ranges were from relative risk 1.08 to 2.5 for a single disease 
allele present to 1.5 to 10.0 for all 6 alleles being disease variants.  For each of the 10 
relative risk levels, 100 replicates were generated to yield 1,000 total genotype files for 
this phase of the study.  GenomeSIM_2_PDA.m and genomeSIM_2_Haploview.m were 
used to convert the files into sm_PDA and HAPLOVIEW format, respectively.  
Individual genotyping was performed by HAPLOVIEW in the command line mode with 
its default settings except for a memory increase from 500MB to 1GB.  Pooled 
genotyping was done by sm_PDA and the effects of sampling error rates from 0% to 5% 
were tested.  
 Errors in allele frequency estimation form pooling result in the sample error 
variances.  They are inherent to pooling and result from DNA quantitation methods, 
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uneven mixing to form the pools, and the sensitivity (minimum resolvable allelic 
frequency difference) of the genotyping platform.   This error can be reduced reliably to 
<5% [37, 54], and as little as 1% in the absence of experimental bias [37, 55]. The Pooled 
DNA Analyzer code allows the user to specify the level of sampling error as a parameter 
in one of the edit boxes of the PDA graphical user interface.  The sampling error rate is 
incorporated into the association testing statistic by PDA and the variance due to 
sampling error for pooling (V2 of Equation 1) is derived directly from the sampling error.  
The results are shown in Figure 10.  
 
Equation 1: Pooled association testing statistic. 
 the variance due to sampling error is represented by “V2” and highlighted 
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Figure10: Effect of Sampling Error (1% - 5%) on pooled genotyping 
versus individual genotyping: 
 
 
Datapoints are average p-values of 100 simulations 
Additive Complex Disease Model 
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 Individual genotyping resolved all three disease associated SNPs at relative risk 
of 1.5.  Pooled genotyping with a 1% rate of sampling error resolved 2 of the 3 disease 
SNPs at relative risk 1.5, while all three SNPs were detected at the next relative risk level 
of 1.67.  A 2% sampling error rate increased the minimum resolvable relative risk one 
more level to 1.83.  When the sampling error was 3%, minimum resolvable relative risk 
increased by two levels to 2.17.  At sampling error rates of 4% and 5%, none of the 
disease SNPs had p-values surpassing the threshold cutoff of <5e-2 for any of the relative 
risk values tested. 
 Overall, the effect of sampling error on pooled genotyping was to dramatically 
reduce the significance of the disease associate variant p-values at all levels of relative 
risk tested.  As tested, the effect of sampling error increases the minimum resolvable 
relative risk at which the association testing p-values of the disease associated SNPs 
exceeds the threshold p-value.  In cases of 4% and 5% sample error, the p-values of the 
causal SNPs were weakened by 4 to 5 orders of magnitude compared to individual 
genotyping or pooling with 0% sampling error.  This reduction in p-value significance 
results in none of the disease associated SNPs having p-values more significant than our 
threshold of <5e-2. 
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CHAPTER V 
 
 
DISCUSSION 
 
 
Allele frequency parameter for complex disease models 
 For this study, a minor allele frequency (MAF) of 0.20 was chosen based on the 
average MAF in the Caucasian (CEU), Han Chinese/Japanese (CHB+JPT), and African 
Yoruba (YRI) HAPMAP populations [26, 35, 41].  The Illumina HumanHAP550 
genotyping platform shows that the mean minor allele frequencies (MAF) on a genome-
wide scale from the total allele frequency distributions are 0.23, 0.21 and 0.22 for the 
CEU, CHB+JPT and YRI populations, respectively [56].  Median MAFs are 0.23 for 
CEU, 0.20 for CHB+JPT, and 0.21 for the YRI populations.  See Figure 11. 
   
  
Figure 11: Distribution of Minor Allele Frequencies (MAF) in human 
HAPMAP populations. 
 Determined by Illumina HumanHAP550 genotyping platform 
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[56] 
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 As additional evidence for this decision of setting the MAF of the disease 
associated variants at 0.20, several highly publicized genome-wide association studies on 
type 2 diabetes (T2D) are cited [6, 12-14, 47].  These studies have lead to a very 
promising advance in the understanding of T2D by finding or expanding the number of 
disease associated variants to 10 for T2D.  For example, Sladeck and Rocheleua et. al. 
[12] report that 7 of the 8 T2D associated SNPs in their findings had MAFs from 0.23 to 
0.35.  The odds ratios of 7 of the 8 the associated SNPs are tightly clustered and range 
from 1.15 to 1.26 for the heterozygous and 1.36 to 1.53 for the homozygous state.  These 
results are shown in Table 4.   
 
  
Table 4: type-2 diabetes GWA by Sladek et. al [12]:
Column listings: 1) disease associated SNP name, 2) chromosome, 3) 
position, 4) risk allele, 5) major allele, 6) MAF of cases, 7) MAF of controls, 
8) odds ratios of heterozygotes (het), and 9) odds ratios of homozygotes 
(hom) [12] 
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 The picture emerges of many risk variants, each having a small and similar 
magnitude of effect on disease probability.  Thus, there is strong support that T2D is a 
complex disease with an additive type allelic spectrum.  The top ranked SNP had a higher 
odds ratio of 1.65 for the heterozygous state and 2.77 for the homozygous state, as well 
as a higher MAF of 0.40.  The higher MAF and odds ratio of the top ranking SNP likely 
contributed to the fact that it was the first of T2D associated variants to be found [57].  
TCF7L2 was previously associated with T2D by Grant et. al. in 2006.  This finding itself 
evolved from previous work that suggested chromosome 10 (among others) housed a 
T2D associated region [58].  Importantly, this TCF7L2 association was confirmed in 
genotypically distinct and diverse populations [59-61], this was a critical finding for a 
true disease associated variant in humans and not just a spurious genotyping anomaly of a 
subset.  The current group of T2D associated SNPs was found by genome-wide 
association studies.  These studies were able to confirm the TCF7L2 variant found 
previously.  In addition, several more T2D associated SNPs were also discovered.  All of 
the novel SNPs have lower relative risk or odds ratios than TCF7L2 [12-14, 47] and thus 
lower effect size towards disease contribution.  This progress is truly exciting in terms of 
the pace at which understanding the nature of complex diseases such as T2D is 
accelerating.  The story continues to progress and the methods continue to evolve.  The 
diabetes risk variant question is far from answered; the fact that the list of confirmed 
genetic variants associated with T2D has increased by an order of magnitude in only the 
first round of genome-wide association studies suggests that there may be even more 
associated variants to be found. 
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 The results of the diabetes studies serve as a validation of model parameter 
choices in as far as they are realistic and seen in the real world.  The MAF was fixed at 
0.20 for all genotype files and was the first parameter of the models that was decided, 
based on the diabetes data and HAPMAP data.  
 
Relative risk ranges for complex disease models 
 Once the MAF of 0.20 was chosen, the range of relative risks was the next 
parameter to consider.  One of the first genome-wide studies to be conducted was by 
Klein et. al. on age-related macular degeneration (AMD) in 2005 [62].  The conclusion 
was that 2 variants within the complement factor H (CFH) region were associated with 
AMD.  The study found that the odds ratios of the two associated SNPs were 4.6 to 4.7 
for heterozygotes and 7.5 for homozygotes.  Concurrently, a linkage screen and 
resequencing on a candidate region in chromosome 1q32 by Haines et. al. co-confirmed 
that alleles within the CFH region were associated with AMD [63].  The odds ratios for 
these variants ranged from 2.45 to 5.5.  These results point to a relatively large effect size 
from a few markers and as such were used as a soft upper ceiling for the model 
construction parameters in the evaluation.  Complex disease is characterized as having 
many disease markers each with a modest affect, and as such ranges of odds ratios well 
below the AMD study results were also evaluated.  In contrast to the AMD allelic spectra 
of 2 disease variants with large odds ratios (2.5 to 7.5); the type 2 diabetes profile has 8-
10 associated variants each with much smaller odds ratio; 1.19 is the smallest 
heterozygote odds ration and 2.77 is the largest homozygous odds ratio (Table 4) [12-14, 
47, 57, 59-61].  The T2D data was used as a guide to model additive complex disease.  
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The smallest odds ratio used in this study is 1.07 (multiplicative model) or 1.08 (additive 
model) representing heterozygotes in 1 of markers with 1 disease associated variant 
present [“AaBBCC”, “AABbCC”, or “AABBCc”] (Penetrance Table 1).  The maximum 
relative risk on the study was 10.0 (multiplicative and additive models) corresponding to 
homozygotes in all 3 markers [“aabbcc”] (Penetrance Table 10).  The characteristics of 
the penetrance tables are better described by the ranges of relative risks that they cover.  
For example Penetrance table 1 has a relative risk of 1.07 and 1.08 for the multiplicative 
and additive models with a single disease variant, and increases the relative risks in 
proportion to the number of variants present in the genotypes up to relative risk 1.5 for 6 
disease alleles.  The model equations are based on the complex disease formulas derived 
from the Risch and Teng models for complex disease [40] and listed in Equation 4 for the 
additive model and Equation 7 for the multiplicative model. 
 
Equation 4: General penetrance probability calculation for additive 
complex disease model  
 
Penetrance probability for additive complex disease model 
(f) = [ f0 + '
 

( ] * (number of disease associated alleles) 
 
Equation 7: General penetrance probability calculation for 
multiplicative complex disease model  
 
Penetrance probability for multiplicative complex disease model  
(f) = ## $%#   
0   &  '

(  
 
 The result is a distribution of relative risk levels which conform to the Risch and 
Teng model definition, while being expanded to a 3 locus model with 27 combinatoric 
76   
genotype possibilities.  This results in the range of relative risks for the least penetrant 
model being 1.07 for 1 variant to 1.5 for 6 variants in the smallest effect models 
(Penetrance Table 1) and the most penetrant model having relative risks ranging from  
2.5 for 1 variant present to relative risk 10.0 with 6 disease associated variants 
(Penetrance Table 10).  Penetrance Tables 1-10 are listed in the Appendix.  
  
Population sample sizes parameters for complex disease models  
 One the parameter choices of MAF at 0.20 and the relative risk ranges were set in 
the complex disease parameters, the range of sample sizes was the next parameter to 
define.  A study by Zou and Zhao looked at the effect of genotyping and sampling errors 
on the sample size required to achieve statistical significance in association studies [39].  
This evaluation used the Risch and Teng complex disease models as a basis for genotype 
and penetrance value constructions [48].  The genotype state of wild-type “AA” is 
represented as (f0), “Aa” for a single disease allele heterozygote by (f1), and “aa” for 2 
disease variant homozygote by (f2).  The additive model penetrance probability 
parameters were [f0 = 0.01, f1 = 0.025, f2 = 0.04] thus having a relative risk of 2.5 for the 
heterozygote and 4.0 for the homozygote double mutant.  The multiplicative model 
parameters were [f0 = 0.01, f1 = 0.020, f2 = 0.04] yielding relative risk of 2.0 for the 
heterozygote and 4.0 for the homozygous double mutant.  Both models had several levels 
of associated allele frequencies (0.5, 0.20, and 0.7).  For individual and pooled 
genotyping with 0% genotype error and 0% sampling error, a sample size of 322 was 
needed to achieve 80% power with a significance level of <5e-8 for the additive model.  
The multiplicative model needed a larger sample size, 404 to achieve the same statistical 
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power.  Error rates of 0% (perfect genotyping and no sampling error) are a theoretical 
baseline for the calculations, not a practical one. When the genotyping error rate was 
increased to 3% (the maximum amount tested in the study), the sample size required for 
significance increased modestly from 322 to 376 in the additive model and from 404 to 
473 samples required for the multiplicative model.  These effects of genotyping error are 
significant, but relatively small when compared to the effects of sampling error.  
Introduction of sampling error in the pooled genotyping testing had a much more 
dramatic effect.  A 1% sampling error rate increased the sample size required for the 
multiplicative model from 404 to 693, and the additive model form 322 to 479.  Further, 
at a sampling error rate of 3%, Zou and Zhao claim that it is not statistically possible to 
achieve a 5e-8 level of significance with any sample size.   
 Our results somewhat agree with those of the Zou and Zhao.  In general, our 
results show that the genotyping error rate has a modest effect on the overall significance 
of the genome-wide association testing, while sampling error has a dramatically larger 
effect.  Yet, the Zou and Zhao study leaves a wide open gap in the sample size 
requirements needed in the presence of sampling error.  Namely, the sample size required 
goes from 479 (additive model) and 693 (multiplicative model) to ∞ infinity when 
sampling error increases from 1% to 3%.  The fact that the level of significance is set to 
5e-8 implies a stringent correction for multiple testing and is arguably too stringent of a p-
value cutoff [1, 64, 65].  Perhaps a less conservative p-value threshold would have served 
better in increasing the resolution of the Zou and Zhao study.  This would have filled the 
immense gap occurring from the 1% to 3% sampling error rate where the conclusion is 
that anything more than a 1% sampling error rate is a “kiss of death” for pooled 
78   
genotyping association studies.  Our study results use a less stringent cutoff of (p-value 
<5e-2), although it has been argued that this threshold is not stringent enough.  Given that 
our datasets consisted of 10,000 SNPs, a p-value of 5e-2 might yield 500 false positives 
by chance alone along with the true positives.  For the SNP size in our study, this was 
determined as an acceptable amount of “noise”.  For larger SNP numbers in the 100,000 
to 1,000,000 ranges as the current generation of genotyping platforms can achieve, a 
higher threshold will definitely be needed. 
 Our study uses a 3 locus disease model which represents more complex and more 
“real world” model where there are multiple genes contributing to the allelic spectra of 
disease, rather than additive or multiplicative effects of the heterozygous and 
homozygous state of a single locus.  This use of single locus models for simulating 
complex diseases misses the broader issue in that complex diseases are due to multiple 
loci. This is not due to poor research design by previous groups, but rather to the lack of 
the proper computational tools needed to create the proper models.  This was a major 
factor in initiating our study using a multi marker model of complex disease, and using 
genomeSIM as the genotype simulation package in order to achieve it. 
 The choice of sample size was influenced by the results of the type 2 diabetes 
(T2D) and AMD studies.  As a higher sample sized analysis, the T2D GWA used 1,363 
cases and controls to find 8 putative disease associated SNPs with low odds ratios of 1.19 
to 2.77 [12].  As a lower sample sized evaluation, the AMD GWA used 146 cases and 
controls to yield 2 disease associated SNPs with high odds ratios of 4.6 to 7.5 [62].  
These examples can be generalized to show that sample size needed for a GWA is a 
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function of the disease relative risk or odds ratios, the allele frequencies, and the 
significance level cutoff.  
 A schematic from a review by Wang et. al. [1] of sample size required for 
properly powered GWA relative to allele frequency at varying odds ratios is shown in 
Figure 12. 
  
 Figure 12:  Sample size needed in a Genome
study.  
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 The absolute sample size from Figure 12 is not the most important feature of the 
graph.  Different levels of threshold significance or an additive disease model assumption 
instead of multiplicative would change the sample size requirements substantially.  
Rather, it is the shape of the curves and the degree of change from the varying odds ratios 
which is substantial.  As the allele frequencies of the disease associated SNPs becomes 
smaller than 0.05 (or larger than 0.95), there is a sharp exponential increase in the 
required sample size.  This points to the difficulty in terms of large sample sizes needed, 
and therefore large costs, of finding “rare” alleles by GWA.  This boundary between 
common and rare alleles is not precisely defined, but in the context of GWA has been 
eluded at or near (MAF = 0.05).  Indeed the HAPMAP consortium sets this figure as the 
cutoff between “rare” and “common” alleles [27].   
The fact that resolution of rare disease associated alleles requires such large 
sample sizes suggests that even current large scale GWA studies having hundreds, even 
thousands of individuals may still not be adequately powered to detect these rare alleles.  
As individual genotyping is already cost prohibitive when looking for the common 
alleles, the potential usefulness if not necessity of pooled genotyping as a cost effective 
measure in GWA with large sample sizes is highlighted further.   
 In terms of sample size parameter selection for our simulation study, the lower 
sample size requirements of Figure 12 suggest that a multiplicative complex disease SNP 
with an odds ratio of 2.0 and MAF of 0.20 requires a sample size of 200 to 300 
individuals.  The lower odds ratios required much larger sample sizes, ~5,000 individuals 
for odds ratio 1.2 at MAF 0.20.  However, the p-value cutoff in the Wang et. al. figure 
was conservative at p-value <1e-6 and the disease model was multiplicative.  Given the 
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fact that our p-value cutoff was less stringent and we were using an additive model as 
well as a multiplicative model, we set the low end of sample size at 200 individuals (100 
cases and 100 controls).  The fact that the AMD genome-wide association resolved 
highly penetrant markers with a 146 individual sample size reinforced the 200 sample 
size starting point for our simulation parameter.  From there, incremental increases in 
sample sizes were iteratively processed until the significance threshold (p-value < 5e-2) 
for was surpassed at a sample size of 1,000 for pooling with a multiplicative model at the 
highest tested relative risk of 2.5 (Figure 6).  
 The sample size of 500 cases and 500 controls was used for all other sub-sections 
of the study because it represents a “sweet spot” or point of inflection.  In terms of the 
relative risk ranges in our study, the sample size of 1,000 yielded association testing p-
values which exceeded threshold cutoff significance at the highest relative risk range 
tested (2.5 - 10) and did not achieve significance at the lowest relative risk range (1.08 - 
1.5). This was true for both the additive and multiplicative models and also true for both 
individual and pooled genotyping.  Additionally, each combinatoric possibility of above 
or below threshold between individual and pooled genotyping is also seen at the sample 
size of 1,000.  For example, with a sample size of 1,000 in the multiplicative model, 
pooled and individual genotyping both identified all 3 disease associated SNPs at relative 
risk 2.5.  At relative risk 2.0, only individual genotyping resolved all 3 SNPs, while 
pooling found none of them.  At relative risk 1.5, neither pooling nor individual 
genotyping were able to detect any of the SNPs above threshold.  Similar results are seen 
in the additive model.  All 3 SNPs were resolved by pooling and individual genotyping 
at relative risk 2.5 and also 2.0.  At relative risk 1.5, only individual genotyping was able 
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to detect the 3 SNPs, while pooling found none.  The SNPs fell short of the significance 
threshold at a relative risk of 1.33 with the additive model (Figure 7).  Thus, the sample 
size of 1,000 was chosen because it had all of the possible combinations of above or 
below threshold cutoffs; for both additive and multiplicative models; and for both 
individual genotyping and pooling.  All of this occurring within the chosen parameter 
ranges of relative risk 1.08 – 2.5 and MAF 0.20. 
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CHAPTER VI 
 
 
CONCLUSIONS 
 
 
 The objective of this evaluation was to characterize the differences between 
individual genotyping and pooled allelotyping in terms of the nature of loss of resolution.  
This objective was further defined to include sections addressing the comparisons in the 
context of sampling error, genotyping error, relative risk level, sample size, and additive 
or multiplicative allelic disease spectrums. 
 It has been well supported that pooling will introduce an additional source of error 
into genome-wide association (GWA) analysis not present in individual genotyping; 
sampling error [1, 38, 39, 48].  Further, this sampling error can substantially lower the 
statistical power in a pooling based GWA analysis [38, 39].  The effect of sampling error 
in pooled genotyping for our evaluation is shown in Figure 10.  Our results indicate that 
sampling error has a dramatic effect on the overall ability of a GWA to detect the true 
disease associated markers.  Sampling errors of 4% and 5% in the additive complex 
disease model lowered the result significances to the point that none of the disease 
associated variants were detected above threshold.  These results are not as dramatic as 
the Zou and Zhaou study [39] which concluded that it was not possible to achieve a 
significance level of (p-value<5e-8) at 80% power in a GWA using pooled allelotyping 
with 3% sampling error rate.  Another simulation study by Pearson et. al. showed that 
sampling error lowered the rank of the disease associated SNP from #1 out of 100,000 
SNPs by individual genotyping to a rank >5,000 by pooling with 3% sampling error [6].  
This would likely result in exclusion of the SNP out of even the most liberal p-value 
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(<5e-2) threshold cutoff.  The same study concluded that sampling errors of 1% and 2% 
lowered the ranks as well, but to a much lesser degree.  A 2% sampling error rate lead to 
the SNP still ranked within the top 1,000 and a 1% sampling error yielded a top 10 
ranking.  Our results are generally in agreement with the Zou and Pearson data in that 
sampling error is a critical factor and can be tolerated only to a small degree in pooled 
GWA analysis.  Sampling errors of 2% to 3% will significantly impact the overall results 
to the point that the disease associated variants may be lost from the selection criteria 
altogether.  A critical question arises as to overall sampling error rate and, more 
importantly, what minimum sampling error rates are realistically achievable in practice.  
A study by Kirov et. al. found that sampling errors on the Affymetrix 10k genotyping 
platform have a mean error rate of 1.37% [55].  Additionally, 95% of all the SNPs on the 
10K have a rate of error <3.2%.  This evaluation used the Affymetrix 10K Xba 142 2.0 
array.    This in part lead our study to used the 10,000 SNP model with a 2% sampling 
error rate in our study; as sampling error had been well characterized for a real 10,000 
genotyping platform.  The Kirov results cite that the 10K error rate is similar to that of 
genotyping platforms with fewer than 10,000 SNPs.  Whether this error rate scales up to 
the 100k, 500k, and 1 million platforms by Affymetrix (as well as other commercial 
platforms) is unknown.  There are marked differences in Affeymetrix genotyping 
platforms larger than 10K. Firstly, the number of quartets used to probe each SNP was 
reduced from 40 on the 10K array to 24 on the higher number arrays.  Quartets are 
comprised of perfect match and a mismatch for the wild-type and variant alleles.  Thus 
each quartet for a SNP consists of: 1) allele “A” perfect match; 2) allele “A” mismatch; 
3) allele “a” perfect match; 4) allele “a” mismatch.  Additionally, the feature size has 
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been reduced from 8 microns in the 10K array to 5 microns in the higher number SNP 
arrays.  
 Our results for the effect of genotyping error contrast to that of sampling error.  
We found that both individual and pooled genotyping are not as dramatically affected by 
genotyping error as by sampling error.  Although both individual and pooled genotyping 
are significantly affected by genotyping errors to some degree, our results show that this 
is much less of a factor in overall results than the effect of sampling error on pooled 
allelotyping.  We found that genotyping errors even up to 10% were less detrimental than 
a sampling error increase of only 1% (Figure 9).  For the parameters tested (relative risk 
of 2.0 and sample size 1,000) genotyping error up to 10% did not drop any significance 
levels out of the threshold cutoff of <5e-2.  In contrast, a sampling error rate of 3% 
lessened the significance of pooled association testing to well out of the threshold range 
and none of the 3 disease associated variants were detectable.  Future analysis may 
examine this with a lower level of relative risk or fewer samples as the dynamics of 
genotyping error may change at different levels.  The evaluation did not consider 
genotyping error rates greater than 10% as this has been used an indication of “poor 
quality” DNA that has degraded.  Indeed, studies exclude any results where <90% of the 
SNPs are called across the samples or total array platform call rates are <85% [6, 7].  The 
method of genotype error generation by our genotype simulator, genomeSIM, uses a 
uniform random distribution.   
 In terms of allelic spectrum of complex disease, and the differences between 
additive and multiplicative variant resolution for individual and pooled genotyping were 
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examined. Our results conclude that common diseases with an additive allele effect are 
more readily resolved by both individual genotyping and pooling (Figure 13). 
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  Additive Model   Multiplicative model   
 
Figure 13: Individual and Pooled genotyping for Additive and 
Multiplicative models:  
 
Individual genotyping: white squares with black lines:  
Pooled genotyping with 2% sampling error: red circles with red line.   
Cutoff threshold (p-value = 5e-2): blue horizontal line  
 
Data points represent average p-value of 100 simulations 
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 Both individual and pooled genotyping resolved all 3 disease associated variants 
at a lower minimum relative risk in the additive model than the multiplicative model.  
This is not surprising as other groups have suggested that additive common diseases are 
more amenable to GWA analysis in general [1, 16]. Looking at the graph of the allelic 
spectra of the disease models (Figure 2), it is clear that the non-end points of the additive 
model all have a higher disease probability than the corresponding multiplicative model 
points.   
The penetrance functions for disease probability were constructed by making a 3 
locus bi-allelic model. These models would have 27 possible genotype combinations, but 
these states would bin into 7 levels of disease penetrance corresponding to the number of 
disease associated alleles present (0 to 6). The phenocopy rate of 10% was the baseline in 
all of the penetrance functions.  This 10% disease probability phenocopy represents the 
background non-genetic disease probability in all disease model functions where none of 
the disease associated variants are present in the genotype.  The end-point relative risks 
(corresponding to 6 disease associated allele variants in the genotype) ranged from 1.5 to 
10.0.  They were set to cover the ranges of relative risk or odds ratios seen in recent 
GWA analysis[2].  For a low end odds ratios, type 2 diabetes alleles having odds ratios of 
1.19 – 1.3 are cited as examples [12-14, 47].  As a high end of odds ratios, the AMD data 
with odds ratios of 5 to 7 are cited as examples [62, 66, 67] as well as Alzheimer’s ApoE-
ε4 with odds ratios of 3 to 8 [6].   
 Our penetrance functions were created with relative risks as opposed to odds 
ratios.  This was done in order to make the results more general and therefore applicable 
to a range of complex disease characteristics.  The relative risk is defined as the ratio of 
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disease probability given the disease genotype over the probability of disease given the 
disease genotype is not present.  For example a wild-type genotype with disease 
probability of 0.10 and a disease genotype having 1 disease associated SNP and a disease 
probability of 0.20 will have a relative risk of 2.0. The odds ratio is defined as the odds 
of disease given disease genotype over the odds of disease given no disease genotype.  
Using the same probabilities as the previous example, the odds of disease an individual 
with a disease genotype is calculated as the probability of having the disease given 
disease genotype over the probability of not having disease given the disease genotype, 
[0.20/1  0.20 = 0.20/0.80].  The odds of disease in an individual with wild-type 
genotype are [0.10/0.90].  And the odds ratio is the ratio of odds of disease in an 
individual with the disease genotype over the odds of disease in an individual with the 
wild-type genotype +20/80/10/90, = 2.25.  Odds ratio and relative risk 
asymptotically approach each other as they become close to 1, and as such were used 
somewhat interchangeably relating GWA results from the field with our study at the 
levels of relative risk tested.  Odds ratios are more informative than relative risk in 
specific disease examples because they take the odds of disease and non-disease into 
account.  However, relative risk is a more general measure and more appropriate for our 
study as the objective is to examine the general case of common disease rather than a 
specific disease with known odds in the population.  
 The result was the creation of 20 penetrance function to represent additive and 
multiplicative models which low range from relative risks of 1.07 for a single disease 
SNPs to 1.5 for 6 disease SNPs; to a high range of relative risk 2.5 for a single disease 
variant to 10.0 for 6 SNPs.  The multiplicative functions, by definition, will have lower 
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penetrance probabilities in the genotypes with 1 to 5 disease associated SNPs because 
they have the same 0 and 6 disease allele penetrance probabilities as the additive 
functions.  The result is that the causal variants created using the multiplicative model 
penetrance functions were less resolvable than the additive model template.  Further, the 
gap in minimum resolvable relative risk between individual genotyping and pooled 
genotyping was twice as large in the multiplicative model than in the additive model.  
These results suggest that pooled allelotyping is much less viable in identifying common 
disease associated loci with a multiplicative effect characteristic. 
 The choice of a liberal p-value cutoff threshold of 5e-2 was made in the context of 
passing on an acceptable number of putative candidate associations for further analysis.  
This p-value threshold will falsely identify ~500 SNPs from 10,000 SNPs tested as 
disease associated when they are actually due to chance alone.  Other groups have argued 
for the use of a Bonferroni correction to account for multiple testing [22].  Indeed, a p-
value of <5e-2 is useless for genotyping platforms with one million or even 100,000 
SNPs.  For example, using this p-value on a 1,000,000 SNP platform would result in 
~50,000 false positives.  However, Bonferroni assumes independence of SNPs.  Given 
the fact that 70-80% of the human genome is in strong LD [27], the assumption of SNP 
independence does not hold and as a result Bonferroni becomes over stringent.  
Additionally, if Bonferroni is to be used, the sample size required to achieve this “lofty” 
significance level becomes very large.  Alternative strategies have been proposed to 
access proper significance levels such as a Bayesian approach toward determining the 
likelihood a true association [68].  Alternatively, permutation testing offers a good 
solution to empirically assessing the probability of having observed a particular result by 
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chance[16].  Using the association test statistic, a threshold for significance in whole-
genome association analysis can be derived empirically.  Thus, permutation testing can 
be conducted where the status of case or control is randomized in the population and a p-
value is derived from the association test statistic values [69].  The question of proper 
significance levels for GWA studies remains the subject of current research and debate.  
 It has been suggested that a multiphase hybrid design could incorporate pooling as 
the first round “broad” sweep in a genome wide association scan and subsequent 
individual genotyping on candidate regions or SNPs [1, 16, 38].  In this way, the cost 
effective gain in efficiency could be realized by using pooling to generate a list of 
putative associated SNPs.  Even if many of the “associated” SNPs are false positives, 
later rounds of testing would benefit with fewer SNPs to test via the pooled information.  
Our study further supports the position that pooled allelotyping is not a viable 
replacement for individual genotyping, but has the real potential as a useful screening 
tool at the whole-genome level. 
 Our work has created a system which allows for the direct evaluation and 
comparison of pooled allelotyping versus individual genotyping for genome-wide 
association analysis of complex disease.  This was done by using existing bioinformatics 
tools; GenomeSIM for genotype simulations of complex disease [49]; Haploview for 
individual genotyping [50]; and an extensively modified version of the Pooled DNA 
analyzer [51] termed sm_PDA for pooled allelotyping.  Additionally, MATLAB scripts 
to process and parse the files allowed the tools to be connected as a single process.  It is 
clear that pooled allelotyping for genome-wide association studies has both benefits and 
disadvantages.  To be successful, a study will have to carefully weigh these 
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considerations in the experimental design phase.  The potential savings of time and 
money due to less overall genotyping must be carefully weighed against the degree and 
characteristics of power and information reduced in the pooling approach.  Our system 
allows for these considerations to be assessed, evaluated, and compared. 
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APPENDIX A: PENETRANCE TABLES AND MATLAB CODE 
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Penetrance Table 1 for Relative Risk Range 1.08 - 1.50 
 
Uppercase [A, B, or C] denotes non-disease associated allele 
Lowercase [a, b, or c] denotes disease associated variant allele 
 
Heterozygotes for single disease variant locus highlighted in yellow 
Homozygotes for 2 disease variant allele locus highlighted in blue 
 
Disease Associated 
Locus 
Disease Risk 
(Probability) 
A B C Genotype Additive Multiplicative 
AA BB CC AABBCC 0.1000 0.1000 
Aa BB CC AaBBCC 0.1083 0.1070 
AA Bb CC AABbCC 0.1083 0.1070 
AA BB Cc AABBCc 0.1083 0.1070 
aa BB CC aaBBCC 0.1167 0.1145 
Aa Bb CC AaBbCC 0.1167 0.1145 
AA bb CC AAbbCC 0.1167 0.1145 
Aa BB Cc AaBBCc 0.1167 0.1145 
AA Bb Cc AABbCc 0.1167 0.1145 
AA BB cc AABBcc 0.1167 0.1145 
aa Bb CC aaBbCC 0.1250 0.1225 
Aa bb CC AabbCC 0.1250 0.1225 
aa BB Cc aaBBCc 0.1250 0.1225 
Aa Bb Cc AaBbCc 0.1250 0.1225 
AA bb Cc AAbbCc 0.1250 0.1225 
Aa BB cc AaBBcc 0.1250 0.1225 
AA Bb cc AABbcc 0.1250 0.1225 
aa bb CC aabbCC 0.1333 0.1310 
aa Bb Cc aaBbCc 0.1333 0.1310 
Aa bb Cc AabbCc 0.1333 0.1310 
aa BB cc aaBBcc 0.1333 0.1310 
Aa Bb cc AaBbcc 0.1333 0.1310 
AA bb cc AAbbcc 0.1333 0.1310 
aa bb Cc aabbCc 0.1417 0.1402 
aa Bb cc aaBbcc 0.1417 0.1402 
Aa bb cc Aabbcc 0.1417 0.1402 
aa bb cc aabbcc 0.1500 0.1500 
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Penetrance Table 2 for Relative Risk 1.16 – 2.0 
Uppercase [A, B, or C] denotes non-disease associated allele 
Lowercase [a, b, or c] denotes disease associated variant allele 
 
Heterozygotes for single disease variant locus highlighted in yellow 
Homozygotes for 2 disease variant allele locus highlighted in blue 
 
Disease Associated 
Locus   
Disease Risk 
(Probability) 
A B C Genotype Additive Multiplicative 
AA BB CC AABBCC 0.1000 0.1000 
Aa BB CC AaBBCC 0.1167 0.1122 
AA Bb CC AABbCC 0.1167 0.1122 
AA BB Cc AABBCc 0.1167 0.1122 
aa BB CC aaBBCC 0.1333 0.1260 
Aa Bb CC AaBbCC 0.1333 0.1260 
AA bb CC AAbbCC 0.1333 0.1260 
Aa BB Cc AaBBCc 0.1333 0.1260 
AA Bb Cc AABbCc 0.1333 0.1260 
AA BB cc AABBcc 0.1333 0.1260 
aa Bb CC aaBbCC 0.1500 0.1414 
Aa bb CC AabbCC 0.1500 0.1414 
aa BB Cc aaBBCc 0.1500 0.1414 
Aa Bb Cc AaBbCc 0.1500 0.1414 
AA bb Cc AAbbCc 0.1500 0.1414 
Aa BB cc AaBBcc 0.1500 0.1414 
AA Bb cc AABbcc 0.1500 0.1414 
aa bb CC aabbCC 0.1667 0.1587 
aa Bb Cc aaBbCc 0.1667 0.1587 
Aa bb Cc AabbCc 0.1667 0.1587 
aa BB cc aaBBcc 0.1667 0.1587 
Aa Bb cc AaBbcc 0.1667 0.1587 
AA bb cc AAbbcc 0.1667 0.1587 
aa bb Cc aabbCc 0.1833 0.1782 
aa Bb cc aaBbcc 0.1833 0.1782 
Aa bb cc Aabbcc 0.1833 0.1782 
aa bb cc aabbcc 0.2000 0.2000 
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Penetrance Table 3 for Relative Risk 1.33 – 3.0 
Uppercase [A, B, or C] denotes non-disease associated allele 
Lowercase [a, b, or c] denotes disease associated variant allele 
 
Heterozygotes for single disease variant locus highlighted in yellow 
Homozygotes for 2 disease variant allele locus highlighted in blue 
 
Disease Associated Locus 
  
Disease Risk (Probability) 
A B C Genotype Additive Multiplicative 
AA BB CC AABBCC 0.1000 0.1000 
Aa BB CC AaBBCC 0.1333 0.1201 
AA Bb CC AABbCC 0.1333 0.1201 
AA BB Cc AABBCc 0.1333 0.1201 
aa BB CC aaBBCC 0.1667 0.1442 
Aa Bb CC AaBbCC 0.1667 0.1442 
AA bb CC AAbbCC 0.1667 0.1442 
Aa BB Cc AaBBCc 0.1667 0.1442 
AA Bb Cc AABbCc 0.1667 0.1442 
AA BB cc AABBcc 0.1667 0.1442 
aa Bb CC aaBbCC 0.2000 0.1732 
Aa bb CC AabbCC 0.2000 0.1732 
aa BB Cc aaBBCc 0.2000 0.1732 
Aa Bb Cc AaBbCc 0.2000 0.1732 
AA bb Cc AAbbCc 0.2000 0.1732 
Aa BB cc AaBBcc 0.2000 0.1732 
AA Bb cc AABbcc 0.2000 0.1732 
aa bb CC aabbCC 0.2333 0.2080 
aa Bb Cc aaBbCc 0.2333 0.2080 
Aa bb Cc AabbCc 0.2333 0.2080 
aa BB cc aaBBcc 0.2333 0.2080 
Aa Bb cc AaBbcc 0.2333 0.2080 
AA bb cc AAbbcc 0.2333 0.2080 
aa bb Cc aabbCc 0.2667 0.2498 
aa Bb cc aaBbcc 0.2667 0.2498 
Aa bb cc Aabbcc 0.2667 0.2498 
aa bb cc aabbcc 0.3000 0.3000 
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Penetrance Table 4 for Relative Risk 1.5 – 4.0 
Uppercase [A, B, or C] denotes non-disease associated allele 
Lowercase [a, b, or c] denotes disease associated variant allele 
 
Heterozygotes for single disease variant locus highlighted in yellow 
Homozygotes for 2 disease variant allele locus highlighted in blue 
 
Disease Associated Locus 
  
Disease Risk (Probability) 
A B C Genotype Additive Multiplicative 
AA BB CC AABBCC 0.1000 0.1000 
Aa BB CC AaBBCC 0.1500 0.1260 
AA Bb CC AABbCC 0.1500 0.1260 
AA BB Cc AABBCc 0.1500 0.1260 
aa BB CC aaBBCC 0.2000 0.1587 
Aa Bb CC AaBbCC 0.2000 0.1587 
AA bb CC AAbbCC 0.2000 0.1587 
Aa BB Cc AaBBCc 0.2000 0.1587 
AA Bb Cc AABbCc 0.2000 0.1587 
AA BB cc AABBcc 0.2000 0.1587 
aa Bb CC aaBbCC 0.2500 0.2000 
Aa bb CC AabbCC 0.2500 0.2000 
aa BB Cc aaBBCc 0.2500 0.2000 
Aa Bb Cc AaBbCc 0.2500 0.2000 
AA bb Cc AAbbCc 0.2500 0.2000 
Aa BB cc AaBBcc 0.2500 0.2000 
AA Bb cc AABbcc 0.2500 0.2000 
aa bb CC aabbCC 0.3000 0.2520 
aa Bb Cc aaBbCc 0.3000 0.2520 
Aa bb Cc AabbCc 0.3000 0.2520 
aa BB cc aaBBcc 0.3000 0.2520 
Aa Bb cc AaBbcc 0.3000 0.2520 
AA bb cc AAbbcc 0.3000 0.2520 
aa bb Cc aabbCc 0.3500 0.3175 
aa Bb cc aaBbcc 0.3500 0.3175 
Aa bb cc Aabbcc 0.3500 0.3175 
aa bb cc aabbcc 0.4000 0.4000 
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Penetrance Table 5 for Relative Risk 1.66 – 5.0 
Uppercase [A, B, or C] denotes non-disease associated allele 
Lowercase [a, b, or c] denotes disease associated variant allele 
 
Heterozygotes for single disease variant locus highlighted in yellow 
Homozygotes for 2 disease variant allele locus highlighted in blue 
 
Disease Associated Locus 
  
Disease Risk (Probability) 
A B C Genotype Additive Multiplicative 
AA BB CC AABBCC 0.1000 0.1000 
Aa BB CC AaBBCC 0.1667 0.1308 
AA Bb CC AABbCC 0.1667 0.1308 
AA BB Cc AABBCc 0.1667 0.1308 
aa BB CC aaBBCC 0.2333 0.1710 
Aa Bb CC AaBbCC 0.2333 0.1710 
AA bb CC AAbbCC 0.2333 0.1710 
Aa BB Cc AaBBCc 0.2333 0.1710 
AA Bb Cc AABbCc 0.2333 0.1710 
AA BB cc AABBcc 0.2333 0.1710 
aa Bb CC aaBbCC 0.3000 0.2236 
Aa bb CC AabbCC 0.3000 0.2236 
aa BB Cc aaBBCc 0.3000 0.2236 
Aa Bb Cc AaBbCc 0.3000 0.2236 
AA bb Cc AAbbCc 0.3000 0.2236 
Aa BB cc AaBBcc 0.3000 0.2236 
AA Bb cc AABbcc 0.3000 0.2236 
aa bb CC aabbCC 0.3667 0.2924 
aa Bb Cc aaBbCc 0.3667 0.2924 
Aa bb Cc AabbCc 0.3667 0.2924 
aa BB cc aaBBcc 0.3667 0.2924 
Aa Bb cc AaBbcc 0.3667 0.2924 
AA bb cc AAbbcc 0.3667 0.2924 
aa bb Cc aabbCc 0.4333 0.3824 
aa Bb cc aaBbcc 0.4333 0.3824 
Aa bb cc Aabbcc 0.4333 0.3824 
aa bb cc aabbcc 0.5000 0.5000 
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Penetrance Table 6 for Relative Risk 1.83 – 6.0 
Uppercase [A, B, or C] denotes non-disease associated allele 
Lowercase [a, b, or c] denotes disease associated variant allele 
 
Heterozygotes for single disease variant locus highlighted in yellow 
Homozygotes for 2 disease variant allele locus highlighted in blue 
 
Disease Associated Locus 
  
Disease Risk (Probability) 
A B C Genotype Additive Multiplicative 
AA BB CC AABBCC 0.1000 0.1000 
Aa BB CC AaBBCC 0.1833 0.1348 
AA Bb CC AABbCC 0.1833 0.1348 
AA BB Cc AABBCc 0.1833 0.1348 
aa BB CC aaBBCC 0.2667 0.1817 
Aa Bb CC AaBbCC 0.2667 0.1817 
AA bb CC AAbbCC 0.2667 0.1817 
Aa BB Cc AaBBCc 0.2667 0.1817 
AA Bb Cc AABbCc 0.2667 0.1817 
AA BB cc AABBcc 0.2667 0.1817 
aa Bb CC aaBbCC 0.3500 0.2449 
Aa bb CC AabbCC 0.3500 0.2449 
aa BB Cc aaBBCc 0.3500 0.2449 
Aa Bb Cc AaBbCc 0.3500 0.2449 
AA bb Cc AAbbCc 0.3500 0.2449 
Aa BB cc AaBBcc 0.3500 0.2449 
AA Bb cc AABbcc 0.3500 0.2449 
aa bb CC aabbCC 0.4333 0.3302 
aa Bb Cc aaBbCc 0.4333 0.3302 
Aa bb Cc AabbCc 0.4333 0.3302 
aa BB cc aaBBcc 0.4333 0.3302 
Aa Bb cc AaBbcc 0.4333 0.3302 
AA bb cc AAbbcc 0.4333 0.3302 
aa bb Cc aabbCc 0.5167 0.4451 
aa Bb cc aaBbcc 0.5167 0.4451 
Aa bb cc Aabbcc 0.5167 0.4451 
aa bb cc aabbcc 0.6000 0.6000 
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Penetrance Table 7 for Relative Risk 2.0 – 7.0 
Uppercase [A, B, or C] denotes non-disease associated allele 
Lowercase [a, b, or c] denotes disease associated variant allele 
 
Heterozygotes for single disease variant locus highlighted in yellow 
Homozygotes for 2 disease variant allele locus highlighted in blue 
 
Disease Associated Locus 
  
Disease Risk (Probability) 
A B C Genotype Additive Multiplicative 
AA BB CC AABBCC 0.1000 0.1000 
Aa BB CC AaBBCC 0.2000 0.1383 
AA Bb CC AABbCC 0.2000 0.1383 
AA BB Cc AABBCc 0.2000 0.1383 
aa BB CC aaBBCC 0.3000 0.1913 
Aa Bb CC AaBbCC 0.3000 0.1913 
AA bb CC AAbbCC 0.3000 0.1913 
Aa BB Cc AaBBCc 0.3000 0.1913 
AA Bb Cc AABbCc 0.3000 0.1913 
AA BB cc AABBcc 0.3000 0.1913 
aa Bb CC aaBbCC 0.4000 0.2646 
Aa bb CC AabbCC 0.4000 0.2646 
aa BB Cc aaBBCc 0.4000 0.2646 
Aa Bb Cc AaBbCc 0.4000 0.2646 
AA bb Cc AAbbCc 0.4000 0.2646 
Aa BB cc AaBBcc 0.4000 0.2646 
AA Bb cc AABbcc 0.4000 0.2646 
aa bb CC aabbCC 0.5000 0.3659 
aa Bb Cc aaBbCc 0.5000 0.3659 
Aa bb Cc AabbCc 0.5000 0.3659 
aa BB cc aaBBcc 0.5000 0.3659 
Aa Bb cc AaBbcc 0.5000 0.3659 
AA bb cc AAbbcc 0.5000 0.3659 
aa bb Cc aabbCc 0.6000 0.5061 
aa Bb cc aaBbcc 0.6000 0.5061 
Aa bb cc Aabbcc 0.6000 0.5061 
aa bb cc aabbcc 0.7000 0.7000 
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Penetrance Table 8 for Relative Risk 2.16 – 8.0 
Uppercase [A, B, or C] denotes non-disease associated allele 
Lowercase [a, b, or c] denotes disease associated variant allele 
 
Heterozygotes for single disease variant locus highlighted in yellow 
Homozygotes for 2 disease variant allele locus highlighted in blue 
 
Disease Associated Locus 
  
Disease Risk (Probability) 
A B C Genotype Additive Multiplicative 
AA BB CC AABBCC 0.1000 0.1000 
Aa BB CC AaBBCC 0.2167 0.1414 
AA Bb CC AABbCC 0.2167 0.1414 
AA BB Cc AABBCc 0.2167 0.1414 
aa BB CC aaBBCC 0.3333 0.2000 
Aa Bb CC AaBbCC 0.3333 0.2000 
AA bb CC AAbbCC 0.3333 0.2000 
Aa BB Cc AaBBCc 0.3333 0.2000 
AA Bb Cc AABbCc 0.3333 0.2000 
AA BB cc AABBcc 0.3333 0.2000 
aa Bb CC aaBbCC 0.4500 0.2828 
Aa bb CC AabbCC 0.4500 0.2828 
aa BB Cc aaBBCc 0.4500 0.2828 
Aa Bb Cc AaBbCc 0.4500 0.2828 
AA bb Cc AAbbCc 0.4500 0.2828 
Aa BB cc AaBBcc 0.4500 0.2828 
AA Bb cc AABbcc 0.4500 0.2828 
aa bb CC aabbCC 0.5667 0.4000 
aa Bb Cc aaBbCc 0.5667 0.4000 
Aa bb Cc AabbCc 0.5667 0.4000 
aa BB cc aaBBcc 0.5667 0.4000 
Aa Bb cc AaBbcc 0.5667 0.4000 
AA bb cc AAbbcc 0.5667 0.4000 
aa bb Cc aabbCc 0.6833 0.5657 
aa Bb cc aaBbcc 0.6833 0.5657 
Aa bb cc Aabbcc 0.6833 0.5657 
aa bb cc aabbcc 0.8000 0.8000 
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Penetrance Table 9 for Relative Risk 2.33 – 9.0 
Uppercase [A, B, or C] denotes non-disease associated allele 
Lowercase [a, b, or c] denotes disease associated variant allele 
 
Heterozygotes for single disease variant locus highlighted in yellow 
Homozygotes for 2 disease variant allele locus highlighted in blue 
 
Disease Associated Locus 
  
Disease Risk (Probability) 
A B C Genotype Additive Multiplicative 
AA BB CC AABBCC 0.1000 0.1000 
Aa BB CC AaBBCC 0.2333 0.1442 
AA Bb CC AABbCC 0.2333 0.1442 
AA BB Cc AABBCc 0.2333 0.1442 
aa BB CC aaBBCC 0.3667 0.2080 
Aa Bb CC AaBbCC 0.3667 0.2080 
AA bb CC AAbbCC 0.3667 0.2080 
Aa BB Cc AaBBCc 0.3667 0.2080 
AA Bb Cc AABbCc 0.3667 0.2080 
AA BB cc AABBcc 0.3667 0.2080 
aa Bb CC aaBbCC 0.5000 0.3000 
Aa bb CC AabbCC 0.5000 0.3000 
aa BB Cc aaBBCc 0.5000 0.3000 
Aa Bb Cc AaBbCc 0.5000 0.3000 
AA bb Cc AAbbCc 0.5000 0.3000 
Aa BB cc AaBBcc 0.5000 0.3000 
AA Bb cc AABbcc 0.5000 0.3000 
aa bb CC aabbCC 0.6333 0.4327 
aa Bb Cc aaBbCc 0.6333 0.4327 
Aa bb Cc AabbCc 0.6333 0.4327 
aa BB cc aaBBcc 0.6333 0.4327 
Aa Bb cc AaBbcc 0.6333 0.4327 
AA bb cc AAbbcc 0.6333 0.4327 
aa bb Cc aabbCc 0.7667 0.6240 
aa Bb cc aaBbcc 0.7667 0.6240 
Aa bb cc Aabbcc 0.7667 0.6240 
aa bb cc aabbcc 0.9000 0.9000 
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Penetrance Table 10 for Relative Risk 2.5 – 10.0 
Uppercase [A, B, or C] denotes non-disease associated allele 
Lowercase [a, b, or c] denotes disease associated variant allele 
 
Heterozygotes for single disease variant locus highlighted in yellow 
Homozygotes for 2 disease variant allele locus highlighted in blue 
 
Disease Associated Locus 
  
Disease Risk (Probability) 
A B C Genotype Additive Multiplicative 
AA BB CC AABBCC 0.1000 0.1000 
Aa BB CC AaBBCC 0.2500 0.1468 
AA Bb CC AABbCC 0.2500 0.1468 
AA BB Cc AABBCc 0.2500 0.1468 
aa BB CC aaBBCC 0.4000 0.2154 
Aa Bb CC AaBbCC 0.4000 0.2154 
AA bb CC AAbbCC 0.4000 0.2154 
Aa BB Cc AaBBCc 0.4000 0.2154 
AA Bb Cc AABbCc 0.4000 0.2154 
AA BB cc AABBcc 0.4000 0.2154 
aa Bb CC aaBbCC 0.5500 0.3162 
Aa bb CC AabbCC 0.5500 0.3162 
aa BB Cc aaBBCc 0.5500 0.3162 
Aa Bb Cc AaBbCc 0.5500 0.3162 
AA bb Cc AAbbCc 0.5500 0.3162 
Aa BB cc AaBBcc 0.5500 0.3162 
AA Bb cc AABbcc 0.5500 0.3162 
aa bb CC aabbCC 0.7000 0.4642 
aa Bb Cc aaBbCc 0.7000 0.4642 
Aa bb Cc AabbCc 0.7000 0.4642 
aa BB cc aaBBcc 0.7000 0.4642 
Aa Bb cc AaBbcc 0.7000 0.4642 
AA bb cc AAbbcc 0.7000 0.4642 
aa bb Cc aabbCc 0.8500 0.6813 
aa Bb cc aaBbcc 0.8500 0.6813 
Aa bb cc Aabbcc 0.8500 0.6813 
aa bb cc aabbcc 1.0000 1.0000 
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CODE: GENOMESIM_2_PDA.M 
 
function [PoolAF SnpName IndPI]  = genomeSIM2PDA(in) 
 
%input (in) = 10,001(1 disease state + 10k SNP)  
    by 200 - 1000 (100-500cases / 100-500 controls) matrix: 
%column 1 = Major Allele Freq for Controls 
%column 2 = Minor Allele Freq for Controls 
%column 3 = Major AF for Cases  
%column 4 - Minor AF for Cases 
 
%output (out) = (number_of_SNPS+1) by 5 matrix 
%   column1 = disease state (1 for control || 2 for case) 
%   column2 = SNP number (name)  
%   column3 = number of samples in pool (cases || controls) 
%   column4 = Major AF 
%   column5 = Minor AF 
%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%% 
 
[number_of_samples number_of_SNPS] = size(in); 
global number_of_cases; 
number_of_cases = length(find(in(:,1)==1)); 
global number_of_controls; 
number_of_controls = length(find(in(:,1)==0)); 
alellefreq = zeros(4,number_of_SNPS); 
controlfreq = zeros(2,number_of_SNPS); 
casefreq = zeros(2,number_of_SNPS); 
for sample_row = 1:number_of_samples 
    if in(sample_row,1)==0 %control sample (non-disease) 
        for ii = 1:number_of_SNPS 
            if in(sample_row,ii)==0 %'aa' = homozygous little 'a' 
                controlfreq(1,ii)=controlfreq(1,ii)+2; 
            elseif in(sample_row,ii)==1 %'Aa' = heterozygous 
                controlfreq(1,ii)=controlfreq(1,ii)+1; 
                controlfreq(2,ii)=controlfreq(2,ii)+1; 
            elseif in(sample_row,ii)==2%'AA' = homozygous big 'A'  
                controlfreq(2,ii)=controlfreq(2,ii)+2; 
            end 
        end 
    elseif in(sample_row,1)==1 %case sample (disease) 
        for ii = 1:number_of_SNPS 
            if in(sample_row,ii)==0 
                casefreq(1,ii)=casefreq(1,ii)+2; 
            elseif in(sample_row,ii)==1 
                casefreq(1,ii)=casefreq(1,ii)+1; 
                casefreq(2,ii)=casefreq(2,ii)+1; 
            elseif in(sample_row,ii)==2 
                casefreq(2,ii)=casefreq(2,ii)+2; 
            end 
        end 
    end 
end 
for jj = 1:number_of_SNPS 
    alellefreq(1,jj) = controlfreq(1,jj)/(controlfreq(1,jj)+ controlfreq(2,jj)); 
    alellefreq(2,jj) = controlfreq(2,jj)/(controlfreq(1,jj)+ controlfreq(2,jj)); 
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    alellefreq(3,jj) = casefreq(1,jj)/(casefreq(1,jj)+ casefreq(2,jj)); 
    alellefreq(4,jj) = casefreq(2,jj)/(casefreq(1,jj)+ casefreq(2,jj)); 
end 
%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%% 
 
alellefreq = alellefreq'; 
out_temp = zeros(number_of_SNPS*2,5); 
PoolAF = zeros(number_of_SNPS*2,5); 
SnpName = zeros(number_of_SNPS,1); 
IndPI = ones(number_of_SNPS,4); 
  
% Create column1 = 1 for control, 2 for case 
out_temp(1:number_of_SNPS,1) = 1; 
out_temp(number_of_SNPS+1:end,1) = 2; 
  
% Create column2 = SNP number 
for ii = 1:number_of_SNPS 
    out_temp(ii,2) = ii; 
end 
for jj = 1:number_of_SNPS 
    out_temp(number_of_SNPS+jj,2) = jj; 
end 
  
% Create column3 = number of samples in pool 
out_temp(1:number_of_SNPS,3) = number_of_cases; 
out_temp(number_of_SNPS+1:end,3) = number_of_controls; 
  
% create cols 4 - allele freq controls 
out_temp(1:number_of_SNPS,4) = alellefreq(:,1); 
out_temp(number_of_SNPS+1:end,4) = alellefreq(:,3); 
out_temp(1:number_of_SNPS,5) = alellefreq(:,2); 
out_temp(number_of_SNPS+1:end,5) = alellefreq(:,4); 
  
PoolAF = out_temp; 
SnpName = out_temp(1:number_of_SNPS,2); 
IndPI(:,2) = SnpName(1:number_of_SNPS,1); 
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CODE:  GENOMESIM_2_HAPLOVIEW.M 
 
function [haploviewPED haploviewINF] = genomeSIM2haploview(in) 
  
[samples SNPs] = size(in); 
out=zeros(samples,SNPs*2); 
haploview_header = zeros(samples,6); 
haploviewINF = zeros(samples,2); 
kk = 1; %column counter for 0 and 1 of genotypes 
for ii = 1:samples 
    if mod(ii,100)==0 
        fprintf('\ndone with %d samples\n',ii) 
    end 
    for jj = 1:SNPs % row counter 
        if in(ii,jj)==0 
            out(ii,kk) = 1; 
            out(ii,kk+1)=1; 
        elseif in(ii,jj)==1 
            out(ii,kk)=1; 
            out(ii,kk+1)=2; 
        elseif in(ii,jj)==2 
            out(ii,kk)=2; 
            out(ii,kk+1)=2; 
        end %for jj 
        kk = kk+2; % go forward 2 cols 
    end % for ii 
    kk = 1; %reset out array to begining col of next column 
end % for kk 
  
%create first 6 columns for HAPLOVIEW header 
for qq = 1:samples 
    haploview_header(qq,1) = qq; %sample number 
    haploview_header(qq,2) = 525; %alphanumeric ID for family name 
    %columns 3 and 4 are for father and mother ID in family studies 
    haploview_header(qq,5) = 1; %1 = male , 2 = female 
    haploview_header(qq,6) = in(qq,1)+1; % gSIM infile has (0 = control) 
    % and (1 = case) haploview format needs (1 = case), (2 = control) 
end 
for ww = 1:SNPs 
    haploviewINF(ww,1:2)=ww; 
end 
clear in; 
format short; 
fprintf('\ntime_to_calculate%d \n',toc); 
haploviewPED = cat(2,haploview_header,out); 
fprintf('\ndone_genomeSIM2haploview'); 
% dlmwrite('haploview.ped',haploviewPED,'delimiter','\t'); 
% dlmwrite('haploview.inf',haploviewINF,'delimiter','\t'); 
% fprintf('time_to_DLM write%d \n',toc); 
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CODE: PDA_2_PVAL.M: 
 
function automate_PDA2pval_maf3(error) 
  
rank_matrix = []; 
pval_all_rr_vals=[]; 
stdev_pval_all_rr_vals=[]; 
  
for RR=[4 7 10] 
    for ind = 500 
        for rep = 1:100 
            load_it = sprintf('load PDA_cpr_add_RR%d_maf3_rep%d_se%d.txt',RR,rep,error); 
            eval(load_it); 
            rank_fname = sprintf('PDA_cpr_add_RR%d_maf3_rep%d_se%d',RR,rep,error); 
            a = eval(rank_fname); 
            rank_matrix = cat(1,rank_matrix,a); 
        end %for rep 
  
        % sort 100 rep matrix of RR by pval (col#3) 
        sorted_by_pval = sortrows(rank_matrix,[1 3]); 
        %sorted_by_pval_fname=sprintf('PDA_cpr_matrix_multi_RR%d_ind%d_se%d.txt',RR,ind,error); 
        %dlmwrite(sorted_by_pval_fname,sorted_by_pval,'delimiter','\t'); 
  
        %pull out causal SNPs and average their pval (col #3) of 
        SNP_6_sum = 0;SNP_11_sum = 0;SNP_16_sum = 0; 
        SNP_6_count = 0;SNP_11_count = 0;SNP_16_count = 0; 
        for ii = 1:size(sorted_by_pval,1) 
            if sorted_by_pval(ii,1)==6 
                SNP_6_sum = SNP_6_sum + sorted_by_pval(ii,3); 
                SNP_6_count = SNP_6_count+1; 
            elseif sorted_by_pval(ii,1)==11 
                SNP_11_sum = SNP_11_sum + sorted_by_pval(ii,3); 
                SNP_11_count = SNP_11_count+1; 
            elseif sorted_by_pval(ii,1)==16 
                SNP_16_sum = SNP_16_sum + sorted_by_pval(ii,3); 
                SNP_16_count = SNP_16_count+1; 
            end %sorted_by_pval 
        end % for ii 
  
        % pvals for this RR set of 100 reps 
        stdev_SNPa = std(sorted_by_pval(1:100,3)); 
        stdev_SNPb = std(sorted_by_pval(101:200,3)); 
        stdev_SNPc = std(sorted_by_pval(201:300,3)); 
        average_pval_temp = 
[SNP_6_sum/SNP_6_count;SNP_11_sum/SNP_11_count;SNP_16_sum/SNP_16_count]; 
        average_pval_fname = sprintf('PDA_average_pval_add_RR%d_maf3_se%d.txt',RR,error); 
        stdev_pval_temp = [stdev_SNPa; stdev_SNPb; stdev_SNPc]; 
        stdev_pval_fname = sprintf('PDA_stdev_pval_add_RR%d_maf3_se%d.txt',RR,error); 
        dlmwrite(average_pval_fname, average_pval_temp); 
        dlmwrite(stdev_pval_fname, stdev_pval_temp); 
  
        % concat data with all RR samples 
        pval_all_rr_vals = cat(2,pval_all_rr_vals,average_pval_temp); 
        stdev_pval_all_rr_vals = cat(2,stdev_pval_all_rr_vals,stdev_pval_temp); 
        rank_matrix = []; 
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    end % for ind 
  
    final_pval_fname = sprintf('final_pval_add_RR%d_maf3_se%d.txt',RR,error); 
    dlmwrite(final_pval_fname,pval_all_rr_vals); 
    final_stdev_pval_fname = sprintf('final_pval_stdev_add_RR%d_maf3_se%d.txt',RR,error); 
    %eval(final_pval_fname); 
    dlmwrite(final_stdev_pval_fname,stdev_pval_all_rr_vals); 
end %for RR 
  
110   
CODE: HAPLOVIEW_2_PVAL.M 
 
function automate_HAP2pval.m 
  
rank_matrix = []; 
rank_all_rr_vals=[]; 
pval_all_rr_vals=[]; 
stdev_pval_all_rr_vals=[]; 
  
for param_1 = 0:5 
    %load 100 repition values of RR set into matrix 
    for rep = 1:100 
        load_it = sprintf('load Hap_pval_rank_ge%d_%d.txt',param_1,rep); 
        eval(load_it); 
        rank_fname = sprintf('Hap_pval_rank_ge%d_%d',param_1,rep); 
        a = eval(rank_fname); 
        rank_matrix = cat(1,rank_matrix,a); 
    end %for rep 
     
%     % sort 100 rep matrix of RR by rank  
%     sorted_by_rank = sortrows(rank_matrix,4); 
%     sorted_by_rank_fname=sprintf('HAP_sorted_rank_RR%d.txt',param_1); 
%     dlmwrite(sorted_by_rank_fname,sorted_by_rank,'delimiter','\t'); 
     
    %pull out causal SNPs and average their RANKS (col #3) of 
    %rank matrix 
    SNP_6_sum = 0;SNP_11_sum = 0;SNP_16_sum = 0; 
    SNP_6_count = 0;SNP_11_count = 0;SNP_16_count = 0; 
    for ii = 1:size(rank_matrix,1) 
        if rank_matrix(ii,1)==6 
            SNP_6_sum = SNP_6_sum + rank_matrix(ii,3); 
            SNP_6_count = SNP_6_count+1; 
        elseif rank_matrix(ii,1)==11 
            SNP_11_sum = SNP_11_sum + rank_matrix(ii,3); 
            SNP_11_count = SNP_11_count+1; 
        elseif rank_matrix(ii,1)==16 
            SNP_16_sum = SNP_16_sum + rank_matrix(ii,3); 
            SNP_16_count = SNP_16_count+1; 
        end %if rank_matrix 
    end %for ii 
%      
    average_ranks_temp = 
[SNP_6_sum/SNP_6_count;SNP_11_sum/SNP_11_count;SNP_16_sum/SNP_16_count]; 
    average_ranks_fname = sprintf('HAP_average_rank_ge%d.txt',param_1); 
    dlmwrite(average_ranks_fname, average_ranks_temp);     
    rank_all_rr_vals = cat(2,rank_all_rr_vals,average_ranks_temp); 
%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%% 
  
%     % sort 100 rep matrix of RR by pval (col#3) 
%     sorted_by_pval = sortrows(rank_matrix,3); 
%     sorted_by_pval_fname = sprintf('HAP_sorted_pval_RR%d.txt',param_1); 
%     dlmwrite(sorted_by_pval_fname,sorted_by_pval,'delimiter','\t'); 
    
    %pull out causal SNPs and average their pval (col #3) of 
    %'sorted_by_pval' matrix 
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    SNP_6_sum = 0;SNP_11_sum = 0;SNP_16_sum = 0; 
    SNP_6_count = 0;SNP_11_count = 0;SNP_16_count = 0; 
    for ii = 1:size(rank_matrix,1) 
        if rank_matrix(ii,1)==6 
            SNP_6_sum = SNP_6_sum + rank_matrix(ii,2); 
            SNP_6_count = SNP_6_count+1; 
        elseif rank_matrix(ii,1)==11 
            SNP_11_sum = SNP_11_sum + rank_matrix(ii,2); 
            SNP_11_count = SNP_11_count+1; 
        elseif rank_matrix(ii,1)==16 
            SNP_16_sum = SNP_16_sum + rank_matrix(ii,2); 
            SNP_16_count = SNP_16_count+1; 
        end %rank_matrix 
    end % for ii 
    % pvals for this RR set of 100 reps 
    stdev_SNPa = std(rank_matrix(1:100,3)); 
    stdev_SNPb = std(rank_matrix(101:200,3)); 
    stdev_SNPc = std(rank_matrix(201:300,3)); 
    average_pval_temp = 
[SNP_6_sum/SNP_6_count;SNP_11_sum/SNP_11_count;SNP_16_sum/SNP_16_count]; 
    average_pval_fname = sprintf('HAP_pval_ge%d.txt',param_1); 
    stdev_pval_temp = [stdev_SNPa; stdev_SNPb; stdev_SNPc]; 
    stdev_pval_fname = sprintf('HAP_pval_stdev_ge%d.txt',param_1); 
    dlmwrite(average_pval_fname, average_pval_temp);   
    dlmwrite(stdev_pval_fname, stdev_pval_temp);  
%     ci_SNP_A = bootci(500,bootfun,rank_matrix(1:100,3)); 
%     ci_SNP_B = bootci(500,bootfun,rank_matrix(101:200,3)); 
%     ci_SNP_C = bootci(500,bootfun,rank_matrix(201:300,3)); 
     
    % concat data with all RR samples 
    pval_all_rr_vals = cat(2,pval_all_rr_vals,average_pval_temp); 
    stdev_pval_all_rr_vals = cat(2,stdev_pval_all_rr_vals,stdev_pval_temp); 
    rank_matrix = []; 
end % for param_1 
final_rank_fname = sprintf('final_HAP_rank_ge.txt'); 
%eval(final_rank_fname); 
dlmwrite(final_rank_fname,rank_all_rr_vals); 
final_pval_fname = sprintf('final_HAP_pval_ge.txt'); 
%eval(final_pval_fname); 
dlmwrite(final_pval_fname,pval_all_rr_vals); 
final_stdev_pval_fname = sprintf('final_HAP_pval_stdev_ge.txt'); 
%eval(final_pval_fname); 
dlmwrite(final_stdev_pval_fname,stdev_pval_all_rr_vals); 
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